1 **TITLE PAGE**

2 Manuscript title

3 Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous,

- 4 arterial, or thrombocytopenic events: whole population cohort study in 46 million adults 5
- in England
- 6 Short Title
- 7 COVID-19 vaccines and with major venous, arterial, and thrombocytopenic events
- 8 **Authors**
- 9 CVD-COVID-UK consortium
- 10 Writing committee
- 11 William N Whiteley FRCP (Chair)
- 12 Centre for Clinical Brain Sciences, University of Edinburgh
- 13 Nuffield Department of Population Health University of Oxford
- 14 Samantha Ip PhD
- 15 Department of Public Health and Primary Care, University of Cambridge
- 16 Jennifer A Cooper PhD
- 17 Bristol Population Health Science Institute, University of Bristol
- 18 Thomas Bolton PhD
- 19 Department of Public Health and Primary Care, University of Cambridge
- 20 Spencer Keene MSc
- 21 Department of Public Health and Primary Care, University of Cambridge
- 22 Venexia Walker PhD
- 23 Bristol Medical School: Population Health Sciences, University of Bristol
- 24 Rachel Denholm
- 25 Bristol Population Health Science Institute, University of Bristol
- 26 Ashley Akbari MSc
- 27 Population Data Science, Health Data Research UK, Swansea University
- 28 Efosa Omigie BEng MSc
- 29 NHS Digital
- 30 Sam Hollings PhD
- 31 NHS Digital
- 32 Emanuele Di Angelantonio FRCP
- 33 Department of Public Health and Primary Care, University of Cambridge
- 34 NIHR Blood and Transplant Research Unit in Donor Health and Genomics, University
- of Cambridge 35
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 36

- 37 Institute of Health Informatics, University College London
- 38 Angela Wood PhD*
- 39 Department of Public Health and Primary Care, University of Cambridge
- 40 Jonathan A C Sterne PhD*
- 41 Department of Population Health Sciences, University of Bristol
- 42 NIHR Bristol Biomedical Research Centre
- 43 HDR UK South West
- 44 Cathie Sudlow FRSE*
- 45 BHF Data Science Centre, Health Data Research UK
- 46
- 47 *Drs Wood, Sudlow and Sterne contributed equally
- 48
- 49 Word count:
- 50 Abstract: 349
- 51 Manuscript: 3637
- 52
- 53 Corresponding author
- 54 Email: william.whiteley@ed.ac.uk
- 55 Telephone: 07811113610

56 **ABSTRACT**

57 Background:

58 Thromboses in unusual locations after the COVID-19 vaccine ChAdOx1-S have been 59 reported. Better understanding of population-level thrombotic risks after COVID-19 60 vaccination is needed.

61 **Methods**:

62 We analysed linked electronic health records from adults living in England, from 8th 63 December 2020 to 18th March 2021. We estimated incidence rates and hazard ratios 64 (HRs) for major arterial, venous and thrombocytopenic outcomes 1-28 and >28 days 65 after first vaccination dose for ChAdOx1-S and BNT162b2 vaccines. Analyses were 66 performed separately for ages <70 and ≥70 years, and adjusted for age, sex, 67 comorbidities, and social and demographic factors.

68

69 **Results**:

70 Of 46,162,942 adults, 21,193,814 (46%) had their first vaccination during follow-up.

Adjusted HRs 1-28 days after ChAdOx1-S, compared with unvaccinated rates, at ages

72 <70 and ≥70 respectively, were 0.97 (95% CI: 0.90-1.05) and 0.58 (0.53–0.63) for

73 venous thromboses, and 0.90 (0.86-0.95) and 0.76 (0.73-0.79) for arterial thromboses.

74 Corresponding HRs for BNT162b2 were 0.81 (0.74–0.88) and 0.57 (0.53–0.62) for 75 venous thromboses, and 0.94 (0.90-0.99) and 0.72 (0.70-0.75) for arterial thromboses.

75 venous thromboses, and 0.94 (0.90-0.99) and 0.72 (0.70-0.75) for alterial thromboses.
 76 HRs for thrombotic events were higher at younger ages for venous thromboses after

77 ChAdOx1-S, and for arterial thromboses after both vaccines.

Rates of intracranial venous thrombosis (ICVT) and thrombocytopenia in adults aged
<70 years were higher 1-28 days after ChAdOx1-S (adjusted HRs 2.27, 95% CI:1.33–
3.88 and 1.71, 1.35–2.16 respectively), but not after BNT162b2 (0.59, 0.24–1.45 and
1.00, 0.75–1.34) compared with unvaccinated. The corresponding absolute excess
risks of ICVT 1-28 days after ChAdOx1-S were 0.9–3 per million, varying by age and
sex.

84 **Conclusions:**

85 Increases in ICVT and thrombocytopenia after ChAdOx1-S vaccination in adults aged

86 <70 years were small compared with its effect in reducing COVID-19 morbidity and

87 mortality, although more precise estimates for adults <40 years are needed. For

88 people aged ≥70 years, rates of arterial or venous thrombotic, events were generally

89 lower after either vaccine.

90 INTRODUCTION

91 In late February 2021 several groups reported a rare syndrome of thrombosis and 92 thrombocytopenia after vaccination against severe acute respiratory syndrome 93 coronavirus-2 disease 2019 (COVID-19) with ChAdOx1-S (developed by Oxford-94 AstraZeneca).¹⁻³ Thromboses were found in unusual sites such as the cerebral venous 95 sinuses, or mesenteric or portal veins. This syndrome, named 'vaccine-induced immune thrombotic thrombocytopenia' (VITT), is probably due to an autoimmune 96 97 response to platelet factor 4 (PF4) in the absence of exposure to heparin.¹ Whether 98 the risk of common thrombotic illnesses is also increased post-vaccination is 99 uncertain, although there have been reports of post-vaccination ischaemic stroke and intracerebral haemorrhage.^{1,3,4} 100

101 Estimates of vaccine-associated excess risk based on case reports and routine 102 reporting may be biased if diagnostic thresholds vary between vaccinated and 103 unvaccinated individuals or there is less than population-wide coverage. In England, 104 the National Health Service (NHS) provides almost all healthcare; therefore, linked 105 health care records provide comprehensive, population-wide data on outcomes before 106 and after vaccination.⁵ Vaccination in England began on December 8th 2020: the first 107 groups vaccinated were care home residents, then those aged \geq 80 years and frontline 108 health and social care workers. Those clinically extremely vulnerable were invited 109 alongside people aged ≥70 years, and those with other co-morbidities aged <65 110 alongside people aged >65 years. Consequently, individuals vaccinated earlier are 111 expected to have higher rates of venous and arterial events.

We conducted a cohort study using routinely collected, linked health data from multiple
sources, covering almost the entire English adult population (>46 million).
Associations of ChAdOx1-S and BNT162b2 (developed by Pfizer–BioNTech) with

- 115 major venous and arterial events and thrombocytopenic haematological outcomes
- 116 were estimated from the start of the vaccination program to mid-March 2021, before
- 117 VITT surveillance was widespread.

118 METHODS

119 **Population**

120 The study population was adults (aged \geq 18 years), alive and registered with an English 121 NHS general practice on December 8th 2020. The data resource⁵ includes primary 122 care data (General practice extraction service (GPES) data for Pandemic Planning 123 and Research, GDPPR) from 98% of general practices linked at individual-level to 124 nationwide secondary care data including all NHS hospital admissions (Hospital 125 Episode Statistics (HES) and Secondary Uses Service (SUS) data from 1997 126 onwards), COVID-19 laboratory testing data, COVID-19 vaccination data (NHS 127 England immunisation management system), national community drug dispensing 128 data (NHS BSA Dispensed Medicines from 2018) and death registrations. We 129 accessed and analysed pseudonymised data within NHS Digital's secure, privacy 130 protecting Trusted Research Environment.⁶

131 Covariates

132 Covariates were defined from primary care, hospital admissions, community drug 133 dispensing and COVID-19 laboratory testing data, using phenotyping algorithms 134 verified by specialist physicians (see study protocol). Phenotypes for co-morbidities, 135 risk factors and other covariates used Systematized Nomenclature of Medicine 136 Clinical Terms (SNOMED-CT) concepts for primary care data, and ICD-10 codes for 137 hospital admission data. Sex, age, region, deprivation and smoking status were 138 defined as the latest recorded in primary care records before 8th December 2020, and 139 the most recently recorded ethnicity in either primary care or hospital admissions 140 records was used. History of diabetes, depression, obesity, cancer, chronic 141 obstructive pulmonary disease, chronic kidney disease, stroke, MI, DVT or PE, cancer,

thrombophilia, liver disease or dementia were defined as any record in primary care and/or hospital admission data before December 8th 2020. The number of unique diseases in SNOMED-CT for the year before December 8th 2020 were derived from primary care records and major surgery in the previous year from hospital admission records (using the Office of Population Censuses and Surveys classification of surgical procedures).

148 A history of coronavirus (SARS-CoV2) infection was defined as either a positive 149 COVID-19 antigen test in national laboratory data covering swab tests performed in 150 the general population and hospitals or a confirmed COVID-19 diagnosis in primary 151 care or hospital admission records. Prior medication was defined using community 152 dispensing data on all prescriptions dispensed by community pharmacists, appliance 153 contractors, and doctors in England. British National Formulary (BNF) codes were 154 used to define the total number of types of medication prescribed and dispensed in 155 the following groups: antiplatelets, antihypertensives, lipid lowering agents, oral 156 anticoagulants, combined oral contraceptives, and hormone replacement therapy.

157 Outcomes

158 Outcomes were derived from primary care data, hospital admission data (SUS 159 dataset) and the national death registry (see supplementary material).⁷ Specialist 160 clinician-verified SNOMED-CT and ICD-10 rule-based phenotyping algorithms were 161 used to define fatal or non-fatal (i) arterial thrombotic events: myocardial infarction 162 (MI), ischaemic stroke (ischaemic or unclassified stroke, spinal stroke or retinal 163 infarction), other non-stroke non-MI arterial thrombo-embolism; (ii) venous thrombo-164 embolic events: pulmonary embolism (PE), lower limb deep venous thrombosis (DVT), 165 intracranial venous thrombosis (ICVT), portal vein thrombosis, and venous thrombosis 166 at other sites; (iii) thrombocytopenic haematological events: any thrombocytopenia

167 (idiopathic, secondary or unspecified), disseminated intravascular primary. 168 coagulation (DIC), and thrombotic thrombocytopenic purpura (TTP); (iv) death from 169 any cause; (v) other vascular outcomes: haemorrhagic stroke (intracerebral or 170 subarachnoid), and mesenteric thrombus for which available codes did not distinguish 171 between arterial or venous causes; and (vi) lower limb fracture as a control condition 172 unlikely to be affected by vaccination. The event date was the earliest of: start of 173 hospital episode, death, or recorded date of primary care event or consultation. Events 174 within the death registry were identified based on underlying cause of death and in 175 hospital admission data based on the primary cause of the care episode.

176 Statistical analyses

Data were analysed according to a pre-specified plan, published on GitHub on April 27th 2021.⁸ Follow-up was from December 8th 2020 to March 18th 2021, the date the European Medicine Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) discussed the first reported complications of vaccination, after which diagnostic effort is expected to be concentrated in people receiving ChAdOx1-S.⁹ Any cell numbers <5 and any potentially disclosive numbers <10 are not reported exactly but as <5 and <10 respectively.

Follow up time for each person was split into periods before, and 1-28 and >28 days after, first vaccination. Censoring was at the earliest of the outcome, death, March 18th 2021 and, in analyses of specific vaccines, receipt of the other vaccine. Incidence rates per 100,000 people per year were estimated for each outcome, before and 1-28 and >28 days after vaccination.

Cox models with time zero December 8th 2020 were fitted, ensuring that all analyses
accounted for changes in rates of outcome events with calendar time. Hazard ratios

191 comparing the periods 1-28 and >28 days after vaccination with unvaccinated or pre-192 vaccination person-time (reference) were estimated. Cox models were fitted 193 separately by age group (<70 and \geq 70 years), both overall and separately for males 194 and females. All Cox models were stratified by geographic region. For rare outcomes, 195 sex-specific hazard ratios were estimated from vaccine-sex interaction terms. For 196 computational efficiency, each model included data from all people with, and a 10% 197 random sample of people without, the outcome of interest; analyses incorporated 198 inverse probability weights to account for this sampling. Confidence intervals were 199 derived using robust standard errors.

200 Region-; age-sex-region-; and fully-adjusted hazard ratios (HR) for associations of 201 ChAdOx1-S and BNT162b2 with outcome events were estimated. The following 202 covariates were included in all fully-adjusted models: (a) sex, age and age², ethnicity, 203 postcode-derived deprivation level; (b) risk factors for venous thromboses 204 (anticoagulant medication, combined oral contraceptive medication, hormone 205 replacement therapy medication, history of PE or DVT, and history of coronavirus 206 infection); (c) risk factors for arterial thromboses (diabetes, hypertension, smoking, 207 antiplatelet medication, blood pressure lowering medication, lipid lowering medication, 208 anticoagulant medication, history of stroke, and history of MI); (d) further covariates 209 selected using a backwards stepwise procedure with p value threshold 0.2, from 210 models using MI as outcome (separately in the four groups defined by age and sex). 211 The covariates had few missing values (apart from ethnicity, for which the 5.9%) 212 'missing' were included as a separate category); hence all analyses used "complete-213 cases".

Sensitivity analyses examined outcome events recorded as the primary or secondary
reason for admission or death in hospital admissions or death records; fatal outcome

events (those followed by death from any cause within 28-days); and all venous and
all arterial thrombotic outcome events associated with thrombocytopenia. Effect
modification by age, sex, ethnicity, medication, diabetes, deprivation and medical
history was examined for all venous and all arterial thromboses.

Absolute excess risks of ICVT were estimated by applying estimated hazard ratios to incidence rates of first fatal or non-fatal events in decades of age and sex in 2019, derived from linked hospital and death records.

223 The study was approved by the Newcastle & North Tyneside 2 Research Ethics

224 Committee (20/NE/0161), the NHS Digital Data Access Request Service (DARS-NIC-

225 381078-Y9C5K) and the British Heart Foundation Data Science Centre CVD-COVID-

226 UK Approvals and Oversight Board.

Data manipulation and analyses used SQL and Python in Databricks and RStudio (Professional) Version 1.3.1093.1 driven by R Version 4.0.3. All code and phenotypes are available at github.com/BHFDSC/CCU002 02.

230 **RESULTS**

On December 8th 2020, 46,162,942 eligible adults were registered with an English
general practice. By March 18th 2021, 21,193,814 (46%) had received their first
vaccination (8,712,477 BNT162b2; 12,481,337 ChAdOx1-S) (supplementary figure 1).
Post-vaccination person-years of follow up for ages <40, 40-69 and ≥70 years
respectively were, for ChAdOx1-S: 91,206, 417,160 and 401,343 person years; for
BNT162b2: 159,856, 427,874, and 583, 890 person years.

The risks per 100,000 persons from December 8th 2020 to March 18th 2021 were: any

venous thrombosis 45.3, any arterial thrombosis 189; thrombocytopenia 4.2 (Table 1).

239 Risks of venous and arterial thromboses were higher in people with co-morbidities and

240 with increasing age and deprivation, and varied substantially by ethnicity. Absolute 241 and relative increases in risk with increasing age and deprivation were greater for 242 arterial than for venous thromboses. The risk of venous thromboses was higher in 243 people with prior DVT or PE, thrombophilia, or oral anticoagulant medication, while 244 the risk of arterial thromboses was higher in people with prior stroke, MI or antiplatelet 245 medication. The risk of thrombocytopenia increased with age and co-morbidities but 246 varied less markedly with ethnicity and deprivation than the risk of venous or arterial 247 thromboses.

248 Incidence rates of all events varied substantially in unvaccinated and post-vaccination 249 (Table 2). In the unvaccinated, the crude incidence rates per 100,000 person years 250 were: all venous thromboses 141 (mostly PE and DVT), ICVT 1.97; portal vein 251 thrombosis 1.15; any arterial thrombosis 549 (with slightly more ischaemic stroke (273) than MI (268)); any thrombocytopenia 13, with very low rates of DIC (0.12) and 252 253 TTP (0.67). For each vaccine, unadjusted incidence rates of venous and arterial 254 thromboses, haemorrhagic stroke, mesenteric thrombus and thrombocytopenia were 255 higher after than before vaccination in the under 70s, but lower after than before 256 vaccination in the over 70s.

257 The additional confounding factors selected using backward selection were: for both 258 sexes and age strata, previous diagnosis of cancer, number of unique diseases in the 259 last year, surgery in the last year, obesity, liver disease; additionally for women aged 260 <70, history of depression and total number of types of medication (by BNF chapters); 261 additionally for men aged <70, history of SARS-CoV2 infection and thrombocytopenia; 262 and additionally for men and women aged \geq 70, chronic kidney disease and dementia. 263 Crude hazard ratios were substantially attenuated after adjusting for age, and further 264 attenuated after adjusting for confounding factors. For example, in <70 year-olds the

HRs 1-28 days post- versus unvaccinated were attenuated from 2.81 to 2.27 for ICVT;
from 4.85 to 1.71 for thrombocytopenia; and from 3.21 to 0.90 for ischaemic stroke
(supplementary table 1).

In people aged <70 years, the fully adjusted HR for any venous thrombosis was 0.97 (95% CI:0.90-1.05) 1–28 days after ChAdOx1-S compared with before vaccination, with similar adjusted HRs for PE and DVT. Compared with before vaccination, the hazard of any venous thrombosis was lower 1-28 days after ChAdOx1-S in people aged \geq 70 (adjusted HR 0.58, 95%CI:0.53–0.63) and 1–28 days after BNT162b2 (<70: HR 0.81, 0.74–0.88; \geq 70 HR: 0.57, 0.53–0.62), with similar adjusted HRs for PE and DVT. (Figure 1, supplementary table 1).

275 In people aged <70 years, adjusted HRs for ICVT were 2.27 (95%CI: 1.32–3.88) 1-28 276 days after ChAdOx1-S and 0.51 (0.16–1.68) 1-28 days after BNT162b2. HRs were 277 similar in men and women. In a post-hoc analyses, in people aged <40 years, the HRs 278 1-28 days after vaccination were 3.73 (1.58-8.83) and 1.07 (0.33-3.48) for ChAdOx1-279 S and BNT162b2 respectively. The same estimates for people 40-69 years were 1.93 280 (1.19-2.13) and 0.74 (0.29-1.87). In people aged ≥ 70 years, associations of 281 vaccination with ICVT were estimated imprecisely (<10 events for ChAdOx1-S and 8 282 for BNT162b2 (Figure 1, supplementary table 1).

Adjusted HRs for any arterial thrombosis 1-28 days after ChAdOx1-S were 0.90 (95%CI: 0.86-0.95) and 0.76 (0.73–0.79) in people aged <70 and \geq 70 years respectively. Corresponding HRs 1-28 days after BNT162b2 were 0.94 (0.90-0.99) and 0.72 (0.70–0.75). HRs were similar for MI and ischaemic stroke, and >28 days after vaccination (Figure 2, supplementary table 1).

In people aged <70 years, adjusted HRs for thrombocytopenia were 1.71 (95%CI:1.35–2.16) 1–28 days and 1.69 (1.16-2.46) >28 days after ChAdOx1-S. Corresponding HRs after BNT162b2 were 1.00 (0.75-1.34) and 0.97 (0.66-1.41). For those aged ≥70 years, adjusted HRs for thrombocytopenia 1-28 days after vaccination were similar for ChAdOx1 (0.79, 95%CI: 0.56-1.10) and BNT162b2 (0.68, 0.51-0.90) (Figure 3, supplementary table 1).

Adjusted HRs for lower limb fracture 1–28 days after ChAdOx1-S were 0.85 (95% CI:

295 0.77–0.93), and 0.83 (0.78–0.89) in people aged <70 and \geq 70 years respectively.

296 Corresponding HRs after BNT162b2 were 0.93 (0.84–1.02) and 0.69 (0.66–0.73).

297 (Figure 3, supplementary table 1). Adjusted HRs for all-cause mortality 1–28 days after

298 ChAdOx1-S were 0.37 (95%CI: 0.35–0.39), and 0.28 (0.28–0.29) in people aged <70

and ≥70 years respectively. Corresponding HRs after BNT162b2 were 0.24 (0.22-

300 0.26) and 0.19 (0.19–0.20) (supplementary figure 2, supplementary table 1).

301 Subgroup analyses

302 HRs for all venous and for all arterial thrombotic events 1-28 days after vaccination 303 were lower in older age groups for each vaccine (all interaction p values < 0.0001) 304 (supplementary table 2). HRs for venous thromboses were >1 1-28 days after 305 compared with before vaccination in people aged <50 years for ChAdOx1-S but not 306 BNT162b2. HRs for arterial thromboses were >1 1-28 days after compared with before 307 vaccination in people aged <50 years for both ChAdOx1-S and BNT162b2. A higher 308 proportion of venous thromboses in those aged <40 years compared with those aged 309 ≥40 years were due to ICVT. A higher proportion of arterial thromboses at age <40 310 was due to stroke than at ages 40–59 and 60–69 years. Less marked trends for lower 311 HRs in older individuals were observed for HRs >28 days after vaccination. Despite 312 modest differences between the magnitude of HRs in subgroups defined by sex,

ethnicity, prior COVID, COCP, diabetes, deprivation or history of MI, DVT or PE,
anticoagulation or antiplatelet medication, HRs in all of these subgroups were
consistent with lower rates of arterial or venous thromboses after vaccination with
ChAdOx1-S or BNT162b2.

317 Sensitivity analyses

318 When using a less restrictive outcome definition (outcomes recorded as primary or 319 secondary reason for admission), estimated HRs were consistent with those from 320 analyses of outcomes in the primary position (supplementary figure 3). Similarly, 321 estimated HRs for fatal outcomes, were similar to HRs for outcomes in the primary 322 position (supplementary figure 4). There were very few people for whom outcomes in 323 the primary position were recorded as well as thrombocytopenia in any position in the 324 same hospital admission or death record (after ChAdOx1-S and BNT162b 325 respectively: ICVT 7 and 0; all arterial thromboses 47 and 58; all venous thromboses 326 37 and 26).

327 Intracranial venous thrombosis

328 Characteristics were similar among patients who developed ICVT while unvaccinated, 329 after ChAdOx1 and after BNT162b. Most were women (66% unvaccinated, 67% 330 ChAdOx1, 79% BNT162b), of white ethnicity (75% unvaccinated, 92% ChAdOx1, 331 100% BNT162b), and had no prior co-morbidities (71% unvaccinated, 50% ChAdOx1, 50% BNT162b). Patients with post vaccination ICVT were older than those with 332 333 unvaccinated ICVT. Post-vaccination, no patients had a recorded history of 334 thrombophilia, and fewer than 5% had a recorded dispensed prescription of oral 335 contraceptive or HRT (supplementary Table 3).

Applying the HR for ICVT 1-28 days after ChAdOx1 to the monthly incidence of ICVT in 2019, the excess risk of ICVT in the month after vaccination with ChAdOx1 among those aged 19–30, 31–39, 40–49, 50–59 and 60–69-years was estimated to be, respectively: 0.9, 1.1, 1.5, 1.5 and 1.6 per million vaccinated in men and 3.0, 2.7, 2.0, 1.6 and 1.5 per million vaccinated in women.

341 **DISCUSSION**

342 In this cohort study, which included almost all adults alive in England at the start of the 343 national COVID-19 vaccination programme, vaccination with ChAdOx1-S, but not 344 BNT162b2, was associated with approximately 2-fold higher rates of ICVT or 345 hospitalisations due to thrombocytopenia in people aged under 70 years, after 346 adjusting for a comprehensive range of demographic characteristics and 347 comorbidities. The corresponding absolute increases in the risk of these events were 348 very small. ChAdOx1-S and BNT162b2 were associated with lower hazards of major 349 vascular events after vaccination in those aged ≥70 years. Post-hoc analyses stratified 350 by age suggest that in people aged <50 years, rates of venous thromboses were 351 higher 1-28 days after vaccination with ChAdOx1-S, and that rates of arterial 352 thrombotic events were higher 1-28 days after vaccination with ChAdOx1-S or 353 BNT162b2, compared with rates in unvaccinated people.

The large population analysed (including almost 10 times as many vaccinated people as any other published study) adds substantial precision to estimated associations of thromboses with vaccination, which is of particular importance for very rare events and associations in subgroups. The extensive data linkages across different healthcare settings enabled adjustment for a wide range of confounding variables. The analysed population is slightly larger than the mid-year estimate of the 2020 English population

aged \geq 18 (44,456,850) that excluded short-term residents and students, and modelled international migrant numbers.¹⁰

362 Smaller Danish and Norwegian electronic health record studies reported a small excess of intracranial haemorrhage (2 per 100,000 1-28 days after ChAdOx1-S), 363 364 cerebral venous thrombosis (3 per 100,000) and other venous thrombosis (2 per 365 100,000).¹¹ The randomised trials of ChAdOx1-S, reported no venous thrombotic 366 events among 8597 participants who received the vaccine versus two among 367 8581who received placebo.¹² A Scottish study found a risk of of 1.13 (0.62–1.63) 368 cases of idiopathic thrombocytopenic purpura per 100,000 after ChAdOx1-S. There 369 was no clear evidence on other outcomes, although the number of post-vaccine events 370 was small.¹³ Reporting of ICVT cases to the UK Medicines and Healthcare products 371 Regulatory Agency (MHRA) identified more cases of ICVT with thrombocytopenia 372 after ChAdOx1-S than the present study (44 up to 31st March 2021).¹⁴

373 Healthcare systems planning to use ChAdOx1-S should balance the very small harms 374 against the known benefits of the vaccine. For older populations, who are most 375 vulnerable to COVID-19, we found no evidence of increased risk of any event with 376 ChAdOx1-S. In younger populations, who have a lower morbidity and mortality due to 377 COVID-19, other available vaccines might be prioritise, especially when the risk of 378 COVID-19 is otherwise low.

Our study has several limitations. First, identification of exposures, covariates and outcomes relies on the accuracy of data collected during routine healthcare. Additional data on results of laboratory and radiology investigations would have improved diagnostic coding, particularly for ascertainment of thrombocytopenia. Second, people who were not registered with an NHS GP (for example the homeless, recent immigrants, those using only private healthcare and those not eligible for NHS care)

385 or who opted out of their data being provided to NHS Digital were excluded. Third, 386 follow up ended on March 18th 2021, but a small number of events that occurred before 387 this date may have been excluded because they had yet to be coded or the people 388 affected were still in hospital. Analyses after this date will likely lead to overestimation 389 of associations, because speciality societies recommended further investigations of 390 mild symptoms in vaccinated populations. Fourth, our primary outcome used the 391 primary reason for death or hospital admission, which improves the positive predictive 392 value but may lead to an underestimation of incidence. This is necessary because 393 historical non-incident events are frequently recorded in secondary positions. 394 Analyses of events recorded in any position as fatal within 28 days were consistent 395 with the primary analyses. Fifth, we did not address time-varying confounding, which 396 can occur when factors which vary during follow up, such as admission to hospital, 397 predict both vaccination and outcomes of interest. Sixth, comparison of adjusted and 398 unadjusted associations suggests that studies that do not adjust for a comprehensive 399 range of potential confounders will overestimate the thrombotic effects of vaccination. 400 However, adjusted associations in this study may still be biased by unmeasured 401 confounding by patient characteristics that predict both vaccination and thromboses 402 and that are difficult to ascertain in electronic health records. Examples include general 403 health at the time of vaccination, and people at higher risk of thromboses (e.g. with 404 end-stage diseases).¹⁵ There were slightly lower post-vaccination rates of the 405 'negative control' outcome lower limb fracture in those aged \geq 70 years, which implies 406 that this degree of unmeasured confounding may affect results for thrombotic 407 outcomes in that age group.

Associations of vaccination with thromboses varied with age. This may be because inolder people small increases in the risk of major thrombotic events after vaccination

410 with ChAdOx1-S were more than offset by reductions in major thrombotic events 411 (particularly PE) subsequent to COVID-19. By contrast, in younger people any 412 increase in risk associated with ChAdOx1-S vaccine is less likely to be offset by a 413 lower risk of COVID-associated thrombosis, because the chance of severe COVID disease is lower in younger than older individuals. 414 415 Further analyses assessing the effects of other vaccines and the effects of second 416 doses of these vaccines on thrombotic, neurological and cardiac complications will be 417 important to inform vaccination programs. Access to data from radiology or laboratory

systems (which in the UK will rely on regional rather than national data collectionsystems) will allow more comprehensive case ascertainment and more granular

420 phenotyping. Such efforts are currently underway across the UK.

421

422 **DATA SHARING**

423 The de-identified data used in this study is available via the CVD-COVID-UK 424 coordinated BHF Data consortium by Science Centre 425 (https://www.hdruk.ac.uk/projects/cvd-covid-uk-project/) for accredited researchers working on approved projects in the NHS Digital trusted research environment. The 426 427 protocol. analytic and phenotyping code is available studv at: 428 https://github.com/BHFDSC/CCU002 02

429 **FUNDING**

430 The British Heart Foundation Data Science Centre (grant No SP/19/3/34678, awarded 431 to Health Data Research (HDR) UK) funded co-development (with NHS Digital) of the 432 trusted research environment, provision of linked datasets, data access, user software 433 licences, computational usage, and data management and wrangling support. Support 434 was also provided through the Data and Connectivity and Longitudinal Health and 435 Wellbeing National Core Studies, which were established through the UK 436 Government's Chief Scientific Adviser's National Core Studies programme to 437 coordinate COVID-19 priority research. Consortium partner organisations funded the 438 time of contributing data analysts, biostatisticians, epidemiologists, and clinicians.

439 WW is supported by the Chief Scientist's Office (CAF/01/17). CS, AW and WW are supported by Stroke Association (SA CV 20\100018). WW has given expert testimony 440 441 to UK courts.

442 AMW is supported by the BHF-Turing Cardiovascular Data Science Award 443 (BCDSA\100005) and by core funding from UK MRC (MR/L003120/1), BHF 444 (RG/13/13/30194; RG/18/13/33946), and NIHR Cambridge Biomedical Research 445 Centre (BRC-1215-20014). AMW is part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 446 447 116074. The views expressed are those of the author(s) and not necessarily those of 448 the NIHR or the Department of Health and Social Care.

449 JAC, JS, and RD are supported by the Health Data Research (HDR) UK South West 450 Better Care Partnership, and the NIHR Bristol Biomedical Research Centre at 451 University Hospitals Bristol, and Weston NHS Foundation Trust and the University of 452 Bristol.

453 VMW is supported by the Medical Research Council Integrative Epidemiology Unit, 454 which receives its funding from the Medical Research Council and the University of 455 Bristol (MC UU 00011/4).

456 AA, SD is supported by Health Data Research UK (grant number: HDR-9006), which 457 receives its funding from the UK Medical Research Council, Engineering and Physical 458 Sciences Research Council, Economic and Social Research Council, Department of 459 Health and Social Care (England), Chief Scientist Office of the Scottish Government 460 Health and Social Care Directorates, Health and Social Care Research and 461 Development Division (Welsh Government), Public Health Agency (Northern Ireland), 462 British Heart Foundation (BHF) and the Wellcome Trust; and Administrative Data 463 Research UK, which is funded by the Economic and Social Research Council (grant 464 number: ES/S007393/1).

465 This work uses data provided by patients and collected by the NHS as part of their 466 care and support. We would also like to acknowledge all data providers who make

467 anonymised data available for research.

Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication

470 **Conflicts of interest**

471 None

472 **CONTRIBITIONS**

473 WW chaired the writing committee. WW, CS, JS and AW conceived the idea, and 474 prepared the protocol and drafted the manuscript. SI, JAC, SK, VW, TB, RD and JS wrote the analytic code. VW, JAC, SK and SI prepared analytic code for open access 475 476 publication. SI, VW and TB prepared the tables and figures. EO and SH prepared data 477 from NHS Digital. SD, SK and WW prepared phenotype code. AW and JS designed 478 and supervised the statistical analyses. CS is the Director of the BHF Data Science 479 Centre and coordinated approvals for and access to data within the NHS Digital TRE. 480 All authors commented on the protocol, analyses, and manuscript, and approved the 481 final version before submission. All authors had full access to the study data.

482

483 **REFERENCES**

- Schultz NH, Sørvoll IH, Michelsen AE, *et al.* Thrombosis and Thrombocytopenia
 after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021; published online April
 DOI:10.1056/nejmoa2104882.
- 487 2 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S.
 488 Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J*489 *Med* 2021; : NEJMoa2104840.
- Scully M, Singh D, Lown R, *et al.* Pathologic Antibodies to Platelet Factor 4 after
 ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021; : NEJMoa2105385.
- 492 4 Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ,
 493 Hvas A-M. Thrombocytopenia with acute ischemic stroke and bleeding in a
 494 patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J
 495 Thromb Haemost 2021; published online April 20. DOI:10.1111/jth.15347.
- Wood A, Denholm R, Hollings S, *et al.* Linked electronic health records for
 research on a nationwide cohort of more than 54 million people in England: Data
 resource. *BMJ* 2021; **373**. DOI:10.1136/bmj.n826.
- 499 6 Trusted research environment. https://digital.nhs.uk/coronavirus/coronavirus-500 data-services-updates/trusted-research-environment-service-for-england.
- Herrett E, Shah AD, Boggon R, *et al.* Completeness and diagnostic validity of
 recording acute myocardial infarction events in primary care, hospital care,
 disease registry, and national mortality records: cohort study. *BMJ* 2013; **346**:
 f2350.
- 5058BHFDataScienceCentre.Studyprotocol.2021.506https://github.com/BHFDSC/Protocols/blob/main/COVID vaccination and risk of507arterial and venous event BHF DSC v1.2.pdf.
- 5089COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic509events vaccine's benefits currently still outweigh risks Update | European510Medicines Agency. https://www.ema.europa.eu/en/news/covid-19-vaccine-511astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-512benefits (accessed May 10, 2021).
- 513 10 Office for National Statistics. Estimates of the population for the UK, England 514 and and Wales. Scotland Northern Ireland. 2021. 515 https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigratio 516 n/populationestimates/datasets/populationestimatesforukenglandandwalesscot 517 landandnorthernireland.
- 518 11 Pottegård A, Lund LC, Karlstad Ø, *et al.* Arterial events, venous 519 thromboembolism, thrombocytopenia, and bleeding after vaccination with 520 Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based 521 cohort study. *BMJ* 2021; **373**: n1114.
- Voysey M, Costa Clemens SA, Madhi SA, *et al.* Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* 2021; **397**: 881–91.

- 526 13 Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic 527 528 Scotland. Nat *Med* 2021; published online events in June 9. 529 DOI:10.1038/s41591-021-01408-4.
- 530 14 Hunter PR. Thrombosis after covid-19 vaccination. *BMJ* 2021; **373**. 531 DOI:10.1136/BMJ.N958.
- 532 15 OpenSAFELY Collaborative T, Curtis HJ, Inglesby P, *et al.* Trends and clinical 533 characteristics of COVID-19 vaccine recipients: a federated analysis of 57.9 534 million patients' primary care records in situ using OpenSAFELY. *medRxiv* 535 2021; : 2021.01.25.21250356.

536

538

539 **TABLES**

540 Table 1 Numbers of patients analysed and (in parentheses) risk per 100,000 of venous 541 and arterial events and thrombocytopenia (TCP) during follow up, overall and 542 according to age.

- 543 Table 2 Numbers of events and incidence rates pre and post first vaccination. 544 Incidence rate per 100,000 per annum (a) ChAdOx1-S (b) BNT162b2 vaccine
- 545 **FIGURE LEGENDS**
- 546
- Figure 1 Adjusted Hazard ratios for all venous thromboses, intracranial venous
 thromboses, pulmonary embolism and deep vein thromboses after ChAdOx1-S or
 BNT162b2 vaccine.
- **Figure 2** Adjusted hazard ratios for all arterial thromboses, myocardial infarction, ischaemic stroke and other arterial thromboses after ChAdOx1-S or BNT162b2 vaccine.
- 553 **Figure 3** Adjusted hazard ratios for thrombocytopenia haemorrhagic stroke, 554 mesenteric thrombosis, lower limb fracture after ChAdOx1-S or BNT162b2 vaccine

555 SUPPLEMENTARY MATERIAL

- 556 Protocol
- 557 **Supplementary table 1** Unadjusted, age-, sex- and region- adjusted, and fully 558 adjusted hazard ratios for (a) ChAdOx1-S (b) BNT162b2 vaccine
- 559 **Supplementary table 2** Stratum specific estimates for (a) venous and (b) arterial events.
- 561 **Supplementary table 3**. Characteristics of patient who had an ICVT event before and 562 after vaccination. Only percentage are presented, as disclosure control does not allow 563 numbers <5 to be released
- 564 **Supplementary figure 1:** Cumulative frequency of vaccines of different types during 565 follow up
- 566 **Supplementary figure 2**: Adjusted hazard ratios for portal vein thrombosis, other 567 venous events, and death after ChAdOx1-S or BNT162b2 vaccine
- 568 **Supplementary Figure 3** Hazard ratios for major (A) arterial and (B) venous 569 thrombotic events, and (C) haematological events, other events and lower limb 570 fractures recorded in any position in EHR
- 571 **Supplementary Figure 4**: Hazard ratios for major (A) arterial and (B) venous 572 thrombotic events, (C) haematological events, other events and fractures recorded in 573 death record or in hospital record in first position followed by death <28 days

according t	u age.		Ove	rall			Δαε	, <70			Age, ≥70			
	-	All	Venous	Arterial	TCP	All	Venous	Arterial	ТСР	All	Venous	Arterial	ТСР	
N				87,251 (189)	1,926 (4.2)		11,835 (30.5)	38,283 (98.8)	1,167 (3.0)	7,418,771	9,068 (122)	48,968 (660)		
	Male	22,765,779	10,358 (45.5)	51,851 (228)	986 (4.3)		6,406 (33.0)	26.549 (137)	555 (2.9)	3,340,325	3,952 (118)	25,302 (757)	431 (12.9)	
Sex	Female	23,397,163	10,538 (45.3)	35,400 (151)	940 (4.0)		5,429 (28.1)	11,734 (60.7)	612 (3.2)	4,078,446	5,116 (125)	23,666 (580)	328 (8.0)	
	18 - 29	8,821,973	781 (8.9)	/ /		8,821,973			143 (1.6)	4,078,440	5,110 (125)	23,000 (380)	528 (8.0)	
	18 - 29 30 - 49	8,821,973		400 (4.5)	143(1.6)		781 (8.9)	400 (4.5)						
A = -	50 - 49 50 - 69	, ,	3,544 (22.0)	6,424 (39.8)	338 (2.1)		3,544 (22.0)	6,424 (39.8)	338 (2.1)					
Age	50 - 69 70 - 79	13,791,173	7,510 (54.5)	31,459 (228)	686 (5.0)	13,791,173	7,510 (54.5)	31,459 (228)	686 (5.0)	4 (74 072	4 920 (102)	22 240 (470)	419 (9.0)	
		4,674,973	4,820 (103)	22,249 (476)	418 (8.9)					4,674,973	4,820 (103)	22,249 (476)	418 (8.9)	
	80+	2,743,798	4,248 (155)	26,719 (974)	341 (12.4)		155 (12 5)	2 2 2 2 2 2 2	105 (2.0)	2,743,798	4,248 (155)	26,719 (974)	341 (12.4)	
	Asian or Asian British	3,718,442	599 (16.1)	5,325 (143)	152 (4.1)	3,467,223	475 (13.7)	3,378 (97.4)	125 (3.6)	251,219	124 (49.4)	1,947 (775)	27 (10.7)	
	Black or Black British	1,634,470	654 (40.0)	2,086 (128)	58 (3.5)	1,525,603	513 (33.6)	1,384 (90.7)	45 (2.9)	108,867	141 (130)	702 (645)	13 (11.9)	
Ethnicity	Mixed	712,534	182 (25.5)	642 (90.1)	22 (3.1)	682,037	153 (22.4)	426 (62.5)	19 (2.8)	30,497	29 (95.1)	216 (708)	<5 (9.8)	
Etimoley	Other ethnic groups	1,497,133	217 (14.5)	1,072 (71.6)	39 (2.6)	1,427,187	162 (11.4)	678 (47.5)	33 (2.3)	69,946	55 (78.6)	394 (563)	<10 (8.6)	
	White	36,446,855	18,995 (52.1)	77,118 (212)	1,643 (4.5)	29,619,868	10,362 (35.0)	31,821 (107)	939 (3.2)	6,826,987	8,633 (126)	45,297 (663)	704 (10.3)	
	Unknown or missing	2,153,508	256 (11.9)	1,008 (46.8)	12 (0.6)	2,022,253	170 (8.4)	596 (29.5)	6 (0.3)	131,255	86 (65.5)	412 (314)	<10 (4.6)	
	1 - 2	9,118,746	4,565 (50.1)	18,830 (206)	365 (4.0)	8,069,275	3,064 (38.0)	10,493 (130)	272 (3.4)	1,049,471	1,501 (143)	8,337 (794)	93 (8.9)	
	3 - 4	9,567,633	4,105 (42.9)	17,436 (182)	370 (3.9)	8,273,028	2,454 (29.7)	8,370 (101)	234 (2.8)	1,294,605	1,651 (128)	9,066 (700)	136 (10.5)	
Deprivation ¹	5 - 6	9,355,549	4,091 (43.7)	17,642 (189)	392 (4.2)	7,784,840	2,235 (28.7)	7,263 (93.3)	221 (2.8)	1,570,709	1,856 (118)	10,379 (661)	171 (10.9)	
-	7 - 8	9,076,313	4,146 (45.7)	16,939 (187)	381 (4.2)	7,362,375	2,128 (28.9)	6,334 (86.0)	221 (3.0)	1,713,938	2,018 (118)	10,605 (619)	160 (9.3)	
	9 - 10	8,772,902	3,926 (44.8)	16,024 (183)	406 (4.6)	7,000,538	1,908 (27.3)	5,602 (80.0)	210 (3.0)	1,772,364	2,018 (114)	10,422 (588)	196 (11.1)	
a 1.	Current	7,814,045	3,079 (39.4)	16,115 (206)	260 (3.3)	7,287,225	2,492 (34.2)	11,811 (162)	219 (3.0)	526,820	587 (111)	4,304 (817)	41 (7.8)	
Smoking	Former	10,623,072	6,930 (65.2)	31,768 (299)	581 (5.5)	7,826,062	3,233 (41.3)	11,703 (150)	277 (3.5)	2,797,010	3,697 (132)	20,065 (717)	· · ·	
status	Never	25,722,494	10,667 (41.5)	38,701 (150)	1,053 (4.1)	21,674,974	5,929 (27.4)	14,346 (66.2)	643 (3.0)	4,047,520	4,738 (117)	24,355 (602)	410 (10.1)	
	Stroke	727,218	1,020 (140)	21,489 (2,955)	104 (14.3)	286,650	323 (113)	8,147 (2,842)	40 (14.0)	440,568	697 (158)	13,342 (3,028)	64 (14.5)	
	Myocardial infarction	1,189,182	1,436 (121)	24,212 (2,036)	158 (13.3)	485,506	436 (89.8)	10,486 (2,160)	46 (9.5)	703,676	1,000 (142)	13,726 (1,951)	()	
	DVT or PE	603,351	3,263 (541)	4,050 (671)	142 (23.5)	341,788	1,919 (561)	1,377 (403)	76 (22.2)	261,563	1,344 (514)	2,673 (1,022)	66 (25.2)	
	Thrombophilia	44,593	146 (327)	202 (453)	23 (51.6)	38,136	126 (330)	144 (378)	21 (55.1)	6,457	20 (310)	58 (898)	<5 (31.0)	
	Coronavirus infection ²	1,284,984	1,131 (88.0)	4,167 (324)	101 (7.9)	1,124,135	576 (51.2)	1,642 (146)	63 (5.6)	160,849	555 (345)	2,525 (1,570)	38 (23.6)	
	Diabetes	4,069,412	3,654 (89.8)	25,595 (629)	423 (10.4)	2,460,649	1,509 (61.3)	9,949 (404)	205 (8.3)	1,608,763	2,145 (133)	15,646 (973)	· · · ·	
Medical	Depression	9,516,020	6,272 (65.9)	24,146 (254)	500 (5.3)	8,040,590	4,077 (50.7)	12,859 (160)	348 (4.3)	1,475,430	2,195 (199)	11,287 (765)	152 (10.3)	
history	Obesity	10,918,274	8,863 (81.2)	31,194 (286)	679 (6.2)	8,757,004	5,430 (62.0)	15,848 (181)	411 (4.7)	2,161,270	3,433 (159)	15,346 (710)	· · · ·	
mstory	Cancer	6,609,691	5,674 (85.8)	17,827 (270)	786 (11.9)	4,854,822	2,583 (53.2)	4,462 (91.9)	412 (8.5)	1,754,869	3,091 (176)	13,365 (762)	374 (21.3)	
	COPD	1,582,366	2,497 (158)	12,323 (779)	182 (11.5)	714,880	877 (123)	3,839 (537)	76 (10.6)	867,486	1,620 (187)	8,484 (978)	106(12.2)	
	Liver disease	230,243	284 (123)	1,069 (464)	97 (42.1)	173,423	208 (120)	547 (315)	75 (43.2)	56,820	76 (134)	522 (919)	22 (38.7)	
	CKD	2,934,107	4,467 (123)	25,816 (880)	526 (17.9)	978,886	1,179 (120)	5,164 (528)	200 (20.4)	1,955,221	3,288 (168)	20,652 (1,056)	326 (16.7)	
	Major surgery ³	3,995,870	5,407 (132)	24,164 (605)	763 (19.1)	2,773,174	2,735 (98.6)	9,898 (357)	440 (15.9)	1,222,696	2,672 (219)	14,266 (1,167)		
	Dementia	524,293	1,127 (215)	6,073 (1,158)	45 (8.6)	48,821	81 (166)	415 (850)	10 (20.5)	475,472	1,046 (220)	5,658 (1,190)	323 (20.4)	
	Antiplatelet	2,510,382	2,814 (112)	36,415 (1,451)	218 (8.7)	1,000,010	747 (74.7)	15,556 (1,556)	65 (6.5)	1,510,372	2,067 (137)	20,859 (1,381)	153 (10.1)	
	BP lowering	2,510,582	7,969 (92.8)		218 (8.7) 777 (9.0)	4,286,561	2,779 (64.8)	20,579 (480)	305 (7.1)	4,303,299	5,190 (121)	34,883 (811)	472 (11.0)	
	2	, ,		55,462 (646)				, ()				· · · ·	()	
Medications	Lipid lowering	6,808,408	5,796 (85.1)	47,859 (703)	564 (8.3)	3,212,600	1,878 (58.5)	19,543 (608)	194 (6.0)	3,595,808	3,918 (109)	28,316 (787)	370 (10.3)	
	Anticoagulant	1,338,585	2,278 (170)	12,758 (953)	205 (15.3)	381,588	1,144 (300)	2,773 (727)	57 (14.9)	956,997	1,134 (118)	9,985 (1043)	148 (15.5)	
	Oral contraceptive	622,529	138 (22.2)	42 (6.7)	8 (1.3)	622,529	138 (22.2)	42 (6.7)	8 (1.3)	20 7 6	a (72 a)	1.40 (202)	- (
	HRT	540,722	213 (39.4)	516 (95.4)	16 (3.0)	501,957	185 (36.9)	368 (73.3)	14 (2.8)	38,765	28 (72.2)	148 (382)	<5 (5.2)	
Number of	0	36,455,307	12,200 (33.5)	38,617 (106)	980 (2.7)	31,819,272	7,612 (23.9)	18,316 (57.6)	643 (2.0)	4,636,035	4,588 (99.0)	20,301 (438)	337 (7.3)	
diagnoses	1 - 5	9,573,068	8,422 (88.0)	46,012 (481)	925 (9.7)	6,872,479	4,137 (60.2)	19,183 (279)	515 (7.5)	2,700,589	4,285 (159)	26,829 (993)		
	6+	134,567	281 (209)	2,622 (1948)	21 (15.6)	52,420	86 (164)	784 (1496)	9 (17.2)	82,147	195 (237)	1,838 (2,237)	12 (14.6)	
Number of	0	22,970,920	3,679 (16.0)	9,629 (41.9)	321 (1.4)	22,122,043	3,143 (14.2)	7,258 (32.8)	290 (1.3)	848,877	536 (63.1)	2,371 (279)	31 (3.7)	
medications	1 - 5	20,875,516	12,872 (61.7)	56,255 (269)	1,210 (5.8)	· · ·	7,203 (46.1)	25,416 (163)	713 (4.6)	5,256,760	5,669 (108)	30,839 (587)	497 (9.5)	
metheattons	6+	2,316,506	4,352 (188)	21,367 (922)	395 (17.1)	1,003,372	1,489 (148)	5,609 (559)	164 (16.3)	1,313,134	2,863 (218)	15,758 (1,200)	231 (17.6)	

Table 1. Numbers of patients analysed and (in parentheses) risk per 100,000 people of venous and arterial events and thrombocytopenia (TCP), overall and according to age.

¹ Index of Multiple Deprivation deciles where 10 indicates least deprived and 1 indicates most deprived; ² After 31/12/2019 and prior to 08/12/2020; ³ In the last year.

Table 2(a) Numbers and incidence			ion or unvaccinated		accination ≤28 days		accination >28 days
Outcome	Age	N (events)	Incidence rate (95%	N (events)	Incidence rate (95% CI)	N (events)	Incidence rate (95%
All venous	All	14769	140.7 (138.5–143.0)	2006	309.0 (295.8-322.9)	995	382.6 (359.6-407.2)
	<70	9892	104.3 (102.2–106.3)	902	219.5 (205.7–234.3)	234	240.6 (211.7–273.5)
T. 1 .1 1	<u>≥70</u>	4877	484.5 (471.1-498.3)	1104	463.4 (436.9–491.6)	761	467.5 (435.4–501.9)
Intracranial venous thrombosis	All <70	207 188	1.97 (1.72–2.26) 1.98 (1.72–2.29)	27 22	4.16 (2.85–6.06) 5.35 (3.52–8.13)	<10	3.46 (1.80–6.65) 5.14 (2.14–12.35)
	<70 ≥70	19	1.89 (1.20–2.96)	5	2.10(0.87-5.04)	<10	2.45 (0.92–6.54)
Portal vein thrombosis	All	121	1.15 (0.96–1.38)	14	2.16 (0.07 3.04)	9	3.46 (1.80–6.65)
i ortar veni unomoosis	<70	98	1.03(0.85-1.26)	9	2.19 (1.14–4.21)	<5	2.06 (0.51-8.22)
	≥70	23	2.28 (1.52-3.44)	5	2.10(0.87-5.04)	<10	4.30 (2.05–9.01)
Pulmonary embolism	All	8473	80.7 (79.0-82.5)	1203	185.3 (175.1–196.1)	587	225.7 (208.1–244.7)
	<70	5399	56.9 (55.4–58.4)	515	125.3 (114.9–136.6)	134	137.8 (116.3–163.2)
	<u>≥</u> 70	3074	305.3 (294.7–316.3)	688	288.7 (267.9–311.1)	453	278.2 (253.7–305.0)
Deep vein thrombosis	All	5664	54.0 (52.6–55.4)	739	113.8 (105.9–122.3)	374	143.8 (129.9–159.1)
	<70	3971	41.9 (40.6–43.2)	345	83.9 (75.5–93.3)	90	92.5 (75.3–113.8)
	≥70	1693	168.1 (160.3–176.3)	394	165.3 (149.8–182.5)	284	174.4 (155.2–195.9)
Other	All	459	4.37 (3.99–4.79)	51	7.85 (5.97–10.33)	30	11.5 (8.1–16.5)
	$<70 \\ \geq 70$	359 100	3.78 (3.41–4.20) 9.93 (8.16–12.08)	34 17	8.27 (5.91–11.58) 7.13 (4.43–11.47)	21	9.25 (4.81–17.78) 12.9 (8.4–19.8)
All arterial	All	57602	549.1 (544.7–553.6)	8256	1274.4 (1247.2–1302.1)	4634	1787.0 (1736.3–1839.2)
All arterial	All <70	31396	331.0 (327.4–334.7)	8256 2993	729.4 (703.8–756.0)	4634 755	777.4 (723.9–834.9)
	>70	26206	2607.7 (2576.3–2639.5)	5263	2215.7 (2156.7–2276.4)	3879	2391.5 (2317.4–2467.9)
Mvocardial infarction	All	28134	268.1 (265.0–271.3)	3814	587.9 (569.6–606.9)	2050	788.9 (755.5–823.8)
Wivocarciar infarction	<70	17341	182.8 (180.1–185.5)	1628	396.4 (377.6–416.2)	363	373.4 (336.9–413.9)
	≥70	10793	1072.7 (1052.6–1093.1)	2186	918.3 (880.6–957.6)	1687	1037.3 (988.9–1088.0)
Ischaemic stroke	All	28639	272.9 (269.8–276.1)	4334	668.2 (648.6-688.4)	2539	977.6 (940.3–1016.4)
(ischaemic, unknown, retinal and spinal)	<70	13505	142.4 (140.0–144.8)	1309	318.7 (301.9–336.4)	377	387.8 (350.6-429.0)
	≥70	15134	1504.7 (1480.9–1528.9)	3025	1271.6 (1227.1–1317.7)	2162	1330.4 (1275.5–1387.7)
Other arterial	All	1308	12.5 (11.8–13.2)	189	29.1 (25.2–33.6)	98	37.7 (30.9–45.9)
	<70	775	8.17 (7.61–8.76)	82	19.9 (16.1–24.8)	22	22.6 (14.9–34.3)
	≥70	533	52.9 (48.6–57.6)	107	44.9 (37.1–54.2)	76	46.6 (37.3–58.4)
Other	4 11	12	0.12 (0.07, 0.21)		0.46 (0.15, 1.42)		
Disseminated intravascular coagulation	All <70	13 5	$0.12 (0.07 - 0.21) \\ 0.05 (0.02 - 0.13)$	<5 <5	$0.46 (0.15 - 1.43) \\ 0.49 (0.12 - 1.95)$	<5 <5	-
	<70 ≥70	8	0.03(0.02-0.13) 0.79(0.40-1.59)	<5	0.49(0.12-1.93) 0.42(0.06-2.98)	<5	-
Thrombotic thrombocytopenic purpura	All	70	0.67 (0.53–0.84)	<5	0.62 (0.23–1.64)	<5	0.77 (0.19–3.07)
Thromootic thromoocytopenic purputa	<70	64	0.67 (0.53 - 0.84) 0.67 (0.53 - 0.86)	<5	0.02(0.23-1.04) 0.73(0.24-2.26)	<5	2.06 (0.51-8.22)
	≥70	6	0.60 (0.27–1.33)	<5	0.42 (0.06–2.98)	<5	
Any thrombocytopenia	All	1357	12.9 (12.3–13.6)	200	30.8 (26.8–35.4)	89	34.2 (27.8–42.1)
	<70	915	9.64 (9.04–10.29)	124	30.2 (25.3–36.0)	41	42.1 (31.0–57.2)
	≥70	442	43.9 (40.0–48.2)	76	31.9 (25.5–39.9)	48	29.5 (22.2–39.1)
Haemorrhagic stroke	All	3747	35.7 (34.6–36.9)	487	75.0 (68.6-82.0)	289	111.1 (99.0–124.6)
(intra-cerebral or subarachnoid)	<70	2028	21.4 (20.5–22.3)	157	38.2 (32.7–44.7)	45	46.3 (34.5–62.0)
	<u>≥70</u>	1719	170.7 (162.8–179.0)	330	138.4 (124.3–154.2)	244	149.8 (132.1–169.8)
Mesenteric thrombosis	All	1170	11.1(10.5-11.8)	171	26.3(22.7-30.6)	109	41.9(34.7-50.5)
	<70 >70	531 639	5.60 (5.14–6.09) 63.5 (58.7–68.6)	56 115	13.6 (10.5–17.7) 48.2 (40.2–57.9)	20 89	20.6 (13.3–31.9) 54.6 (44.4–67.2)
Lower limb fracture	All	18347	174.9 (172.3–177.4)	2657	409.4 (394.2–425.3)	1632	628.0 (598.3-659.2)
	<70	8732	92.0 (90.1–94.0)	539	131.2 (120.5–142.7)	155	159.4 (136.2–186.5)
	≥70	9615	955.8 (936.9–975.1)	2118	890.0 (852.9–928.7)	1477	908.3 (863.2–955.9)
Death	All	123580	1177.5 (1170.9–1184.1)	16192	2493.1 (2455.0–2531.8)	11738	4510.6 (4429.7–4592.9)
	<70	29802	314.1 (310.5–317.7)	1940	471.9 (451.4–493.4)	897	922.0 (863.6–984.3)
	≥ 70	93778	9312.7 (9253.3–9372.5)	14252	5978.2 (5880.8-6077.1)	10841	6653.3 (6529.2–6779.7)

Table 2(a) Numbers and incidence rates pre-, post-first ChAdOx1-S. Incidence rate per 100,000 person years. Disclosure control prevents presentation of n>5

Table 2(b) Numbers and incluence			on or unvaccinated		ination ≤28 days		accination >28 days
Outcome	Age	N (events)	Incidence rate (95%	N (events)	Incidence rate (95%	N (events)	Incidence rate (95%
All venous	All	14769	140.7 (138.5–143.0) 104.3 (102.2–106.3)	1546	250.1 (237.9–262.9) 154.9 (142.4–168.4)	1587	287.0 (273.2–301.5) 110.8 (98.1–125.2)
	<70	9892	104.3 (102.2–106.3)	548	154.9 (142.4–168.4)	259	110.8 (98.1–125.2)
Y. 1 .1 1	≥70	4877	484.5 (471.1-498.3)	998	377.7 (355.0-401.9)	1328	415.9 (394.1-438.9)
Intracranial venous thrombosis	All <70	207 188	1.97 (1.72–2.26) 1.98 (1.72–2.29)	13 5	2.10 (1.22–3.62) 1.41 (0.59–3.39)	6 <5	1.08 (0.49–2.41) 1.28 (0.41–3.98)
	>70	188	1.89 (1.20–2.96)	8	3.03(1.51-6.05)	<5 <5	0.94 (0.30–2.91)
Portal vein thrombosis	All	121	1.15 (0.96–1.38)	5	0.81 (0.34–1.94)	12	2.17 (1.23–3.82)
	<70	98	1.03 (0.85–1.26)	<5	0.56 (0.14–2.26)	6	2.57 (1.15–5.71)
	≥70	23	2.28 (1.52-3.44)	<5	1.13 (0.37–3.52)	6	1.88 (0.84-4.18)
Pulmonary embolism	All	8473	80.7 (79.0-82.5)	928	150.1 (140.8–160.1)	955	172.7 (162.1–184.0)
	<70	5399	56.9 (55.4–58.4)	306	86.5 (77.3–96.7)	141	60.3 (51.2–71.2)
	≥70	3074	305.3 (294.7–316.3)	622	235.3 (217.6–254.6)	814	254.8 (237.9–273.0)
Deep vein thrombosis	All	5664	54.0 (52.6–55.4)	555	89.8 (82.6–97.6)	590	106.7 (98.4–115.6)
	<70 ≥70	3971 1693	41.9 (40.6–43.2) 168.1 (160.3–176.3)	213 342	60.2 (52.6–68.8) 129.4 (116.4–143.9)	103 487	44.1 (36.3–53.5) 152.4 (139.5–166.6)
Other	All	459	4.37 (3.99–4.79)	55	8.89 (6.83–11.59)	39	7.05 (5.15–9.65)
Other	<70	359	3.78 (3.41–4.20)	28	7.91 (5.46–11.46)	13	5.56 (3.23–9.58)
	>70	100	9.93 (8.16–12.08)	20	10.2 (7.0–14.9)	26	8.14 (5.54–11.95)
All arterial	All	57602	549.1 (544.7–553.6)	7960	1289.8 (1261.7–1318.4)	8799	1594.8 (1561.8–1628.5)
	<70	31396	331.0 (327.4–334.7)	2263	640.2 (614.4–667.2)	876	375.1 (351.1–400.8)
	≥70	26206	2607.7 (2576.3-2639.5)	5697	2160.4 (2105.0-2217.2)	7923	2490.0 (2435.7–2545.4)
Myocardial infarction	All	28134	268.1 (265.0-271.3)	3722	602.5 (583.4-622.2)	4023	728.0 (705.9–750.9)
	<70	17341	182.8 (180.1–185.5)	1285	363.3 (344.0–383.7)	489	209.3 (191.6–228.7)
	≥70	10793	1072.7 (1052.6–1093.1)	2437	922.9 (886.9–960.2)	3534	1107.9 (1072.0–1145.1)
Ischaemic stroke	All	28639	272.9 (269.8–276.1)	4143	670.6 (650.5–691.4)	4702	851.2 (827.2–875.9) 157.9 (142.6–174.9)
(ischaemic, unknown, retinal and spinal)	<70 ≥70	13505 15134	142.4 (140.0–144.8) 1504.7 (1480.9–1528.9)	949 3194	268.2 (251.7–285.9) 1209.9 (1168.6–1252.6)	369 4333	1359.3 (1319.4–1400.4)
Other arterial	All	13134	12.5 (11.8–13.2)	156	25.2 (21.6–29.5)	167	30.2 (25.9–35.1)
	<70	775	8.17 (7.61–8.76)	46	13.0 (9.7–17.3)	26	11.1 (7.6–16.3)
	>70	533	52.9 (48.6–57.6)	110	41.6 (34.5–50.2)	141	44.1 (37.4–52.0)
Other			<u>x</u> , <u>x</u> ,				· · · · · · · · · · · · · · · · · · ·
Disseminated intravascular coagulation	All	13	0.12 (0.07-0.21)	<5	0.32 (0.08–1.29)	<5	0.36 (0.09–1.45)
	<70	5	0.05 (0.02–0.13)	<5	0.28 (0.04–2.01)	<5	-
	≥70	8	0.79 (0.40–1.59)	<5	0.38 (0.05-2.69)	<5	0.63 (0.16-2.50)
Thrombotic thrombocytopenic purpura	All	70	0.67 (0.53–0.84)	<5	0.65 (0.24–1.72)	<5	0.36 (0.09–1.45)
	<70 ≥70	64 6	$0.67 (0.53 - 0.86) \\ 0.60 (0.27 - 1.33)$	<5 <5	0.85(0.27-2.63) 0.38(0.05-2.69)	<5 <5	0.86 (0.21–3.42)
Any thrombocytopenia	All	1357	12.9 (12.3–13.6)	136	22.0 (18.6–26.0)	144	26.0 (22.1–30.6)
Any thrombocytobenia	All <70	915	9.64 (9.04–10.29)	55	15.5(11.9-20.2)	32	13.7 (9.7–19.4)
	≥70	442	43.9 (40.0–48.2)	81	30.6 (24.6–38.1)	112	35.1 (29.1–42.2)
Haemorrhagic stroke	All	3747	35.7 (34.6–36.9)	440	71.2 (64.8–78.1)	579	104.7 (96.5–113.5)
(intra-cerebral or subarachnoid)	<70	2028	21.4 (20.5–22.3)	93	26.3 (21.4–32.2)	55	23.5 (18.1–30.7)
	≥70	1719	170.7 (162.8–179.0)	347	131.3 (118.2–145.8)	524	164.0 (150.6–178.7)
Mesenteric thrombosis	All	1170	11.1 (10.5–11.8)	161	26.0 (22.3-30.4)	217	39.2 (34.3-44.8)
	<70	531	5.60 (5.14-6.09)	28	7.91 (5.46–11.46)	18	7.70 (4.85–12.22)
	≥70	639	63.5 (58.7–68.6)	133	50.3 (42.4–59.6)	199	62.3 (54.2–71.6)
Lower limb fracture	All	18347	174.9 (172.3–177.4)	2573	416.2 (400.5-432.6)	3176	574.6 (554.9–594.9)
	<70 ≥70	8732 9615	92.0 (90.1–94.0) 955.8 (936.9–975.1)	443 2130	125.2 (114.0–137.4)	228	97.6 (85.7–111.1) 923.9 (891.2–957.9)
Dooth	≥/0 All	123580	<u>955.8 (936.9–975.1)</u> 1177.5 (1170.9–1184.1)	9117	<u>806.2 (772.7–841.2)</u> 1474.4 (1444.4–1504.9)	2948 13935	2518.7 (2477.3–2560.9)
Death	All <70	29802	314.1 (310.5–317.7)	775	218.9 (204.0–234.9)	531	2518.7(2477.3-2560.9) 227.2 (208.7-247.4)
	10	27002	517.1 (510.5-517.7)	115			

Table 2(b) Numbers and incidence rates p	e-, post-first BNT162b2. Incidence rate	per 100.000 person ve	ears. Disclosure control	prevents presentation of n>5




Figure 1 Adjusted Hazard ratios for all venous thromboses, intracranial venous thromboses, pulmonary embolism and deep vein thromboses after ChAdOx1-S or BNT162b2 vaccine




Figure 2 Adjusted hazard ratios for all arterial thromboses, myocardial infarction, ischemic stroke and other arterial thromboses after ChAdOx1-S or BNT162b2 vaccine




Figure 3 Adjusted hazard ratios for thrombocytopenia hemorrhagic stroke, mesenteric thrombosis, lower limb fracture after ChAdOx1-S or BNT162b2 vaccine

SUPPLEMENTARY TABLES AND FIGURES

Supplementary Table 1: Hazard ratios (95% CIs) for thrombotic and other outcomes 1-28 and >28 days post-vaccination, compared with pre-vaccination rates. All analyses were stratified on geographical region (A) ChAdOx1-S vaccine (B) BNT162b2 vaccine

Outcome	Age	Sex	1-2	8 days post-vaccination	n	>28 days post vaccination s					
			Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³	Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³			
(A) ChAdOx1-S vaccine											
All venous events	<70	Overall	2.33 (2.16-2.51)	1.32 (1.22–1.43)	0.97 (0.90-1.05)	2.74 (2.39-3.14)	1.60 (1.38–1.84)	0.94 (0.81-1.08)			
		Men	2.68 (2.41-2.97)	1.33 (1.19–1.49)	1.04 (0.93-1.16)	3.13 (2.54-3.84)	1.52 (1.23–1.89)	0.97 (0.78-1.20)			
		Women	2.08 (1.87-2.31)	1.31 (1.17-1.47)	0.96 (0.85-1.07)	2.56 (2.13-3.07)	1.67 (1.38-2.02)	1.02 (0.84-1.23)			
	≥ 70	Overall	0.65 (0.59-0.72)	0.64 (0.59-0.70)	0.58 (0.53-0.63)	0.67 (0.59-0.76)	0.58 (0.52-0.65)	0.49 (0.44-0.55)			
		Men	0.65 (0.56-0.76)	0.65 (0.56-0.74)	0.59 (0.51-0.68)	0.70 (0.58-0.84)	0.63 (0.53-0.75)	0.55 (0.46-0.65)			
		Women	0.65 (0.58-0.74)	0.64 (0.56-0.71)	0.57 (0.50-0.64)	0.64 (0.54-0.76)	0.54 (0.47–0.64)	0.45 (0.39-0.53)			
Intracranial venous thrombosis	<70	Overall	2.81 (1.70-4.64)	2.99 (1.75-5.09)	2.27 (1.33-3.88)	2.37 (0.91-6.12)	2.47 (0.95-6.42)	1.72 (0.66-4.49)			
		Men	2.72 (1.15-6.39)	2.58 (0.99-6.74)	2.06 (0.79-5.37)	3.43 (0.74–15.87)	3.37 (0.71–15.90)	2.40 (0.53-10.86)			
		Women	2.69 (1.45-5.00)	3.27 (1.74-6.17)	2.24 (1.17-4.31)	1.75 (0.52-5.93)	2.14 (0.63-7.22)	1.47 (0.43-5.04)			
	≥ 70	Overall	0.62 (0.17-2.23)	0.65 (0.19-2.21)	0.67 (0.20-2.18)	1.35 (0.13-13.46)	1.13 (0.14–9.20)	1.11 (0.14–9.02)			
		Men	10.8 (3.3-35.8)	8.99 (2.75-29.42)	10.1 (2.7-38.5)	-	-	-			
		Women	0.27 (0.05-1.42)	0.29 (0.06-1.43)	0.28 (0.06-1.34)	0.87 (0.10-7.32)	0.82 (0.11-6.24)	0.76 (0.10-5.70)			
Portal vein thrombosis	<70	Overall	2.49 (1.20-5.14)	1.56 (0.72-3.40)	1.00 (0.24-4.15)	2.76 (0.73-10.51)	1.99 (0.53-7.52)	1.00 (0.06–18.18)			
		Men	3.38 (1.40-8.17)	1.95 (0.76-5.02)	1.22 (0.48-3.08)	3.55 (0.52-24.13)	2.16 (0.32-14.52)	0.98 (0.14-6.75)			
		Women	1.74 (0.48-6.26)	1.06 (0.28-4.07)	0.72 (0.18-2.86)	2.39 (0.37-15.53)	1.57 (0.24–10.12)	0.86 (0.12-6.28)			
	≥ 70	Overall	0.66 (0.11-4.06)	0.67 (0.10-4.24)	0.61 (0.10-3.71)	2.72 (0.49-15.02)	3.00 (0.48–18.99)	2.61 (0.41–16.52)			
		Men	0.43 (0.09-2.09)	0.42 (0.08-2.15)	0.37 (0.07-1.90)	8.60 (2.33-31.70)	7.99 (1.93–33.03)	7.99 (2.03–31.38)			
		Women	0.92 (0.06-13.23)	0.92 (0.06-13.99)	0.82 (0.06-11.05)	0.87 (0.12-6.02)	0.95 (0.12-7.39)	0.86 (0.11-6.92)			
Pulmonary embolism	<70	Overall	2.54 (2.30-2.80)	1.28 (1.15–1.43)	0.95 (0.85-1.05)	3.12 (2.61-3.73)	1.63 (1.34–1.96)	0.95 (0.79–1.15)			
		Men	2.83 (2.46-3.24)	1.27 (1.09-1.48)	1.01 (0.87-1.17)	3.32 (2.52-4.38)	1.43 (1.07–1.91)	0.92 (0.69–1.23)			
		Women	2.35 (2.04-2.70)	1.30 (1.12–1.52)	0.95 (0.82-1.10)	3.09 (2.44-3.92)	1.81 (1.41–2.32)	1.09 (0.85–1.41)			
	≥70	Overall	0.62 (0.55-0.70)	0.60 (0.54-0.68)	0.54 (0.48-0.61)	0.61 (0.52-0.72)	0.54 (0.46-0.62)	0.45 (0.39–0.53)			
		Men	0.63 (0.52-0.75)	0.62 (0.52-0.74)	0.57 (0.47-0.67)	0.63 (0.50-0.79)	0.57 (0.46–0.70)	0.49 (0.40-0.62)			
		Women	0.61 (0.52-0.72)	0.59 (0.51-0.69)	0.53 (0.45-0.61)	0.60 (0.48-0.75)	0.51 (0.42–0.63)	0.43 (0.35–0.53)			
Deep vein thrombosis	<70	Overall	2.08 (1.85-2.34)	1.34 (1.18–1.52)	0.99 (0.87-1.12)	2.37 (1.90-2.96)	1.58 (1.25–1.99)	0.97 (0.77-1.22)			
		Men	2.61 (2.22-3.07)	1.48 (1.25–1.76)	1.15 (0.97–1.36)	2.85 (2.04-3.98)	1.62 (1.14–2.29)	1.06 (0.75-1.50)			
		Women	1.67 (1.40-2.00)	1.21 (1.00-1.46)	0.90 (0.75-1.09)	2.12 (1.57-2.86)	1.57 (1.15–2.13)	1.02 (0.75-1.40)			
	≥ 70	Overall	0.73 (0.62-0.86)	0.71 (0.61-0.83)	0.63 (0.54-0.74)	0.71 (0.57-0.88)	0.62 (0.51-0.75)	0.51 (0.42-0.62)			
		Men	0.72 (0.56-0.94)	0.71 (0.55-0.91)	0.63 (0.49-0.81)	0.77 (0.56-1.06)	0.70 (0.51-0.95)	0.58 (0.42-0.79)			
		Women	0.73 (0.59-0.90)	0.72 (0.59-0.87)	0.64 (0.53-0.77)	0.67 (0.51-0.88)	0.57 (0.45-0.73)	0.47 (0.37-0.60)			
Other	<70	Overall	2.48 (1.70-3.62)	1.60 (1.06-2.40)	1.02 (0.69–1.52)	3.04 (1.54-6.00)	2.04 (1.01-4.09)	0.94 (0.47–1.91)			
		Men	2.61 (1.51-4.53)	1.45 (0.79–2.64)	1.02 (0.57–1.83)	3.17 (1.13-8.90)	1.74 (0.60-5.05)	0.89 (0.31-2.58)			
		Women	2.38 (1.42-4.00)	1.74 (1.01-2.98)	1.12 (0.65–1.91)	3.15 (1.29–7.73)	2.40 (0.97-5.96)	1.26 (0.50-3.17)			
	≥70	Overall	0.46 (0.21–1.01)	0.46 (0.21-0.99)	0.43 (0.20-0.92)	1.13 (0.50-2.54)	1.03 (0.48-2.21)	0.93 (0.42-2.03)			
		Men	0.38 (0.11-1.30)	0.39 (0.12–1.31)	0.33 (0.10-1.08)	1.10 (0.36-3.39)	1.02 (0.34-3.04)	0.79 (0.26-2.36)			
		Women	0.52 (0.19–1.44)	0.51 (0.20-1.36)	0.50 (0.19–1.32)	1.16 (0.37-3.63)	1.03 (0.36-2.98)	0.98 (0.33-2.94)			

Outcome	Age	Sex	1-28	8 days post-vaccination	1	>2	28 days post vaccination s	
	0		Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³	Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³
All arterial events	<70	Overall	3.02 (2.90-3.14)	1.25 (1.20–1.31)	0.90 (0.86-0.95)	3.55 (3.29-3.83)	1.57 (1.45-1.70)	0.91 (0.84-1.00)
		Men	3.42 (3.26-3.60)	1.26 (1.20-1.34)	0.91 (0.86-0.96)	4.70 (4.27-5.17)	1.66 (1.50–1.84)	0.96 (0.86-1.07)
		Women	2.96 (2.76-3.18)	1.24 (1.14–1.34)	0.93 (0.86-1.00)	3.30 (2.90-3.75)	1.43 (1.25–1.64)	0.88 (0.77-1.02)
	≥ 70	Overall	0.89 (0.85-0.93)	0.84 (0.80-0.87)	0.76 (0.73-0.79)	1.03 (0.97-1.10)	0.83 (0.78–0.87)	0.72 (0.68-0.77)
		Men	0.90 (0.85-0.96)	0.87 (0.82-0.92)	0.78 (0.74-0.83)	1.06 (0.97-1.16)	0.89 (0.82-0.96)	0.78 (0.71-0.85)
		Women	0.88 (0.82-0.94)	0.80 (0.76-0.85)	0.73 (0.69-0.78)	1.02 (0.93-1.12)	0.77 (0.71–0.83)	0.68 (0.62-0.74)
Myocardial infarction	<70	Overall	2.85 (2.70-3.01)	1.24 (1.17–1.32)	0.88 (0.83-0.94)	2.93 (2.63-3.26)	1.40 (1.24–1.56)	0.83 (0.73-0.93)
		Men	3.23 (3.02-3.44)	1.25 (1.17–1.35)	0.89 (0.83-0.95)	3.52 (3.08-4.03)	1.33 (1.15–1.53)	0.78 (0.68-0.90)
		Women	2.93 (2.63-3.26)	1.22 (1.09–1.38)	0.92 (0.82-1.04)	3.56 (2.95-4.29)	1.58 (1.29–1.92)	1.01 (0.82–1.24)
	≥70	Overall	0.86 (0.80-0.92)	0.83 (0.78-0.88)	0.76 (0.71–0.81)	0.97 (0.89–1.07)	0.83 (0.76-0.90)	0.74 (0.68–0.81)
		Men	0.88 (0.80-0.96)	0.85 (0.78-0.93)	0.77 (0.71-0.84)	0.96 (0.84-1.09)	0.84 (0.74–0.94)	0.73 (0.64–0.82)
		Women	0.85 (0.76-0.94)	0.80 (0.72-0.88)	0.76 (0.69–0.84)	1.03 (0.90-1.19)	0.82 (0.72–0.93)	0.78 (0.68-0.88)
Ischaemic stroke ⁴	<70	Overall	3.21 (3.02-3.41)	1.25 (1.17–1.34)	0.90 (0.84-0.96)	4.36 (3.91-4.86)	1.76 (1.56–1.98)	0.94 (0.84–1.07)
		Men	3.73 (3.44-4.05)	1.28 (1.17-1.40)	0.91 (0.83-0.99)	6.58 (5.73-7.57)	2.14 (1.84–2.49)	1.12 (0.96–1.31)
		Women	2.91 (2.64-3.20)	1.21 (1.09–1.35)	0.90 (0.81-1.00)	3.10 (2.59-3.71)	1.32 (1.09–1.59)	0.77 (0.63-0.94)
	≥70	Overall	0.92 (0.87-0.98)	0.85 (0.81-0.90)	0.77 (0.73-0.82)	1.08 (0.99-1.18)	0.83 (0.77-0.90)	0.72 (0.67-0.78)
		Men	0.94 (0.85-1.03)	0.89 (0.82-0.96)	0.81 (0.74-0.88)	1.14 (1.01–1.30)	0.93 (0.83-1.04)	0.82 (0.73-0.92)
		Women	0.92 (0.84-1.00)	0.82 (0.77-0.89)	0.75 (0.69-0.80)	1.04 (0.92-1.17)	0.76 (0.68–0.84)	0.66 (0.59-0.73)
Other arterial	<70	Overall	3.18 (2.48-4.07)	1.24 (0.93-1.64)	0.82 (0.63-1.07)	4.20 (2.62-6.73)	1.68 (0.99–2.86)	0.77 (0.46-1.30)
		Men	3.17 (2.29-4.40)	1.05 (0.73-1.51)	0.75 (0.53-1.07)	5.56 (3.07-10.06)	1.66 (0.86–3.20)	0.89 (0.47-1.69)
		Women	3.67 (2.51-5.37)	1.59 (1.03-2.46)	1.04 (0.68–1.59)	3.60 (1.64-7.91)	1.74 (0.73–4.18)	0.83 (0.35-2.01)
	≥70	Overall	0.44 (0.33-0.59)	0.45 (0.34-0.59)	0.41 (0.31–0.53)	0.55 (0.38-0.79)	0.49 (0.35-0.70)	0.44 (0.31-0.63)
		Men	0.46 (0.31-0.67)	0.45 (0.31-0.66)	0.42 (0.29-0.61)	0.61 (0.35-1.05)	0.56 (0.33-0.95)	0.51 (0.30-0.87)
		Women	0.43 (0.28–0.66)	0.44 (0.30-0.67)	0.39 (0.26–0.59)	0.51 (0.30-0.86)	0.44 (0.27–0.71)	0.38 (0.23-0.62)
Haematological events								
Any thrombocytopenia	<70	Overall	4.85 (3.87-6.07)	3.00 (2.34-3.85)	1.71 (1.35–2.16)	7.48 (5.31–10.53)	4.68 (3.24–6.77)	1.69 (1.16-2.46)
		Men	6.47 (4.62–9.06)	3.52 (2.42-5.13)	1.85 (1.30-2.63)	13.2 (8.1–21.4)	6.84 (3.99–11.73)	2.02 (1.18-3.44)
		Women	3.81 (2.80-5.17)	2.65 (1.89-3.71)	1.95 (1.40-2.72)	4.59 (2.78–7.58)	3.34 (1.98–5.64)	2.08 (1.22-3.54)
	≥70	Overall	0.92 (0.65-1.29)	0.87 (0.63-1.22)	0.79 (0.56–1.10)	1.14 (0.66–1.95)	0.99 (0.59–1.65)	0.84 (0.50-1.41)
		Men	0.84 (0.53-1.32)	0.79 (0.50-1.22)	0.68 (0.43-1.06)	1.37 (0.64-2.91)	1.17 (0.57–2.38)	0.92 (0.45-1.90)
		Women	1.04 (0.62–1.75)	0.99 (0.61–1.63)	0.93 (0.56–1.54)	1.02 (0.46-2.24)	0.88 (0.42–1.85)	0.80 (0.38-1.70)
Other events								
Haemorrhagic stroke ⁵	<70	Overall	2.25 (1.88-2.69)	1.05 (0.86–1.27)	1.00 (0.73–1.37)	2.87 (2.10-3.92)	1.39 (1.00–1.93)	1.00 (0.51-1.95)
		Men	2.68 (2.11-3.41)	1.15 (0.89–1.49)	1.01 (0.78–1.30)	2.86 (1.74-4.71)	1.21 (0.72–2.04)	0.87 (0.52-1.46)
		Women	1.93 (1.48-2.52)	0.93 (0.70-1.24)	0.87 (0.66–1.16)	2.94 (1.95-4.42)	1.47 (0.95-2.27)	1.23 (0.80-1.91)
	≥70	Overall	0.83 (0.69–1.00)	0.78 (0.66-0.92)	0.73 (0.62–0.87)	1.09 (0.84–1.40)	0.84 (0.67–1.04)	0.76 (0.61-0.95)
		Men	0.86 (0.65-1.14)	0.82 (0.64–1.05)	0.79 (0.62–1.01)	1.34 (0.93–1.94)	1.03 (0.75–1.43)	0.97 (0.70–1.34)
		Women	0.81 (0.63-1.03)	0.75 (0.60-0.94)	0.70 (0.56-0.87)	0.92 (0.65-1.30)	0.71 (0.52–0.96)	0.64 (0.47-0.86)

Outcome	Age	Sex	1-28	3 days post-vaccination	1	>2	28 days post vaccination s	
	-		Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³	Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³
Mesenteric thrombosis	<70	Overall	3.25 (2.42-4.37)	1.24 (0.89–1.73)	0.84 (0.61–1.16)	5.47 (3.33-8.99)	2.16 (1.24–3.77)	1.04 (0.60-1.80)
		Men	2.87 (1.72-4.77)	0.98 (0.57-1.71)	0.72 (0.43-1.22)	4.34 (1.59–11.83)	1.42 (0.48-4.25)	0.75 (0.26-2.17)
		Women	3.39 (2.36-4.87)	1.43 (0.94-2.17)	1.01 (0.67-1.52)	5.66 (3.21-9.99)	2.59 (1.36-4.94)	1.40 (0.73-2.69)
	≥ 70	Overall	0.66 (0.49-0.89)	0.60 (0.46-0.79)	0.53 (0.41-0.70)	0.95 (0.64-1.43)	0.74 (0.52–1.05)	0.62 (0.43-0.89)
		Men	0.65 (0.39-1.09)	0.61 (0.38-0.98)	0.52 (0.32-0.83)	0.81 (0.44-1.49)	0.69 (0.40-1.18)	0.54 (0.31-0.94)
		Women	0.66 (0.46-0.95)	0.60 (0.44-0.84)	0.55 (0.40-0.77)	1.00 (0.60-1.68)	0.76 (0.48–1.20)	0.67 (0.42-1.08)
Lower limb fracture	<70	Overall	1.71 (1.55–1.87)	1.01 (0.91–1.11)	0.85 (0.77–0.93)	2.26 (1.91-2.67)	1.35 (1.13–1.60)	0.98 (0.83-1.17)
		Men	1.35 (1.15–1.58)	0.98 (0.83-1.16)	0.86 (0.73–1.02)	2.22 (1.67-2.93)	1.60 (1.20-2.14)	1.24 (0.93-1.66)
		Women	1.91 (1.70-2.15)	1.03 (0.91-1.16)	0.88 (0.78-0.99)	2.21 (1.80-2.72)	1.25 (1.01–1.55)	0.95 (0.77-1.18)
	≥70	Overall	1.11 (1.02–1.21)	0.94 (0.88-1.01)	0.83 (0.78–0.89)	1.56 (1.39–1.76)	0.95 (0.87-1.04)	0.78 (0.71-0.85)
		Men	1.06 (0.90-1.24)	0.94 (0.83-1.08)	0.84 (0.73–0.95)	1.50 (1.19-1.89)	0.97 (0.81–1.17)	0.81 (0.67-0.97)
		Women	1.11 (1.01–1.22)	0.95 (0.88-1.03)	0.84 (0.77–0.91)	1.51 (1.32–1.73)	0.95 (0.85–1.06)	0.78 (0.70-0.87)
Death	<70	Overall	1.96 (1.87-2.06)	0.60 (0.57-0.63)	0.37 (0.35-0.39)	4.51 (4.20-4.85)	1.41 (1.30–1.53)	0.51 (0.47-0.56)
		Men	2.35 (2.20-2.51)	0.63 (0.58-0.67)	0.44 (0.41-0.47)	6.47 (5.87-7.13)	1.57 (1.40–1.75)	0.75 (0.67-0.85)
		Women	1.69 (1.56-1.82)	0.56 (0.52-0.61)	0.36 (0.33-0.39)	3.48 (3.13-3.89)	1.21 (1.07–1.37)	0.50 (0.44-0.57)
	≥ 70	Overall	0.35 (0.34-0.36)	0.34 (0.33-0.35)	0.28 (0.28-0.29)	0.49 (0.47-0.51)	0.38 (0.37-0.39)	0.27 (0.26-0.28)
		Men	0.31 (0.30-0.32)	0.32 (0.31-0.33)	0.26 (0.25-0.27)	0.44 (0.42-0.47)	0.37 (0.35-0.38)	0.26 (0.24-0.27)
		Women	0.39 (0.37-0.40)	0.36 (0.35-0.37)	0.30 (0.29-0.31)	0.54 (0.51-0.56)	0.39 (0.38–0.41)	0.29 (0.27-0.30)

All venous events	<70 ≥70 <70 ≥70	Overall Men Women Overall Men Overall Men Overall Men	Unadjusted ¹ 1.47 (1.35–1.61) 1.98 (1.75–2.23) 1.20 (1.06–1.37) 0.65 (0.60–0.71) 0.67 (0.59–0.76) 0.64 (0.58–0.72) 0.76 (0.31–1.85) 1.60 (0.50–5.16) 0.39 (0.10–1.60)	Age and sex adjusted ² 1.01 (0.93–1.11) 1.15 (1.01–1.30) 0.91 (0.80–1.03) 0.56 (0.52–0.61) 0.59 (0.52–0.66) 0.54 (0.49–0.60) 0.72 (0.29–1.78) 1.39 (0.43–4.49)	Fully adjusted³ 0.81 (0.74–0.88) 0.92 (0.81–1.05) 0.74 (0.65–0.84) 0.57 (0.53–0.62) 0.60 (0.53–0.67) 0.56 (0.50–0.63)	Unadjusted ¹ 1.14 (1.01–1.29) 1.56 (1.28–1.89) 1.01 (0.86–1.20) 0.68 (0.62–0.75) 0.75 (0.65–0.87) 0.63 (0.56–0.72)	Age and sex adjusted ² 0.88 (0.77–1.00) 1.02 (0.83–1.25) 0.81 (0.69–0.96) 0.50 (0.46–0.55) 0.59 (0.51–0.68)	Fully adjusted ³ 0.73 (0.64–0.83) 0.83 (0.68–1.02) 0.70 (0.59–0.83) 0.50 (0.45–0.55) 0.58 (0.50–0.67)
All venous events	≥70 <70	Men Women Overall Men Overall Men Women Overall	$\begin{array}{c} 1.98 \left(1.75 - 2.23\right) \\ 1.20 \left(1.06 - 1.37\right) \\ \hline 0.65 \left(0.60 - 0.71\right) \\ 0.67 \left(0.59 - 0.76\right) \\ 0.64 \left(0.58 - 0.72\right) \\ \hline 0.76 \left(0.31 - 1.85\right) \\ 1.60 \left(0.50 - 5.16\right) \\ 0.39 \left(0.10 - 1.60\right) \end{array}$	1.15 (1.01–1.30) 0.91 (0.80–1.03) 0.56 (0.52–0.61) 0.59 (0.52–0.66) 0.54 (0.49–0.60) 0.72 (0.29–1.78)	0.92 (0.81–1.05) 0.74 (0.65–0.84) 0.57 (0.53–0.62) 0.60 (0.53–0.67) 0.56 (0.50–0.63)	1.56 (1.28–1.89) 1.01 (0.86–1.20) 0.68 (0.62–0.75) 0.75 (0.65–0.87)	1.02 (0.83–1.25) 0.81 (0.69–0.96) 0.50 (0.46–0.55) 0.59 (0.51–0.68)	0.83 (0.68–1.02) 0.70 (0.59–0.83) 0.50 (0.45–0.55)
Intracranial venous thrombosis	<70	WomenOverallMenOverallMenWomenOverall	$\begin{array}{c} 1.20 \left(1.06 - 1.37\right) \\ \hline 0.65 \left(0.60 - 0.71\right) \\ 0.67 \left(0.59 - 0.76\right) \\ \hline 0.64 \left(0.58 - 0.72\right) \\ \hline 0.76 \left(0.31 - 1.85\right) \\ 1.60 \left(0.50 - 5.16\right) \\ \hline 0.39 \left(0.10 - 1.60\right) \end{array}$	0.91 (0.80–1.03) 0.56 (0.52–0.61) 0.59 (0.52–0.66) 0.54 (0.49–0.60) 0.72 (0.29–1.78)	0.74 (0.65–0.84) 0.57 (0.53–0.62) 0.60 (0.53–0.67) 0.56 (0.50–0.63)	1.01 (0.86–1.20) 0.68 (0.62–0.75) 0.75 (0.65–0.87)	0.81 (0.69–0.96) 0.50 (0.46–0.55) 0.59 (0.51–0.68)	0.70 (0.59–0.83) 0.50 (0.45–0.55)
Intracranial venous thrombosis	<70	Overall Men Women Overall Men Women Overall	0.65 (0.60–0.71) 0.67 (0.59–0.76) 0.64 (0.58–0.72) 0.76 (0.31–1.85) 1.60 (0.50–5.16) 0.39 (0.10–1.60)	0.56 (0.52–0.61) 0.59 (0.52–0.66) 0.54 (0.49–0.60) 0.72 (0.29–1.78)	0.57 (0.53–0.62) 0.60 (0.53–0.67) 0.56 (0.50–0.63)	0.68 (0.62–0.75) 0.75 (0.65–0.87)	0.50 (0.46–0.55) 0.59 (0.51–0.68)	0.50 (0.45-0.55)
Intracranial venous thrombosis	<70	Men Women Overall Men Women Overall	0.67 (0.59–0.76) 0.64 (0.58–0.72) 0.76 (0.31–1.85) 1.60 (0.50–5.16) 0.39 (0.10–1.60)	0.59 (0.52–0.66) 0.54 (0.49–0.60) 0.72 (0.29–1.78)	0.60 (0.53–0.67) 0.56 (0.50–0.63)	0.75 (0.65–0.87)	0.59 (0.51–0.68)	(
_		Women Overall Men Women Overall	0.64 (0.58–0.72) 0.76 (0.31–1.85) 1.60 (0.50–5.16) 0.39 (0.10–1.60)	0.54 (0.49–0.60) 0.72 (0.29–1.78)	0.56 (0.50-0.63)			0.58 (0.50-0.67)
_		Overall Men Women Overall	0.76 (0.31–1.85) 1.60 (0.50–5.16) 0.39 (0.10–1.60)	0.72 (0.29–1.78)		0 62 (0 56 0 72)		
_		Men Women Overall	1.60 (0.50–5.16) 0.39 (0.10–1.60)				0.45 (0.40-0.51)	0.45 (0.40-0.52)
-	≥70	Women Overall	0.39 (0.10-1.60)	$1.39(0.43 \pm 4.49)$	0.59 (0.24–1.45)	0.65 (0.20–2.13)	0.59 (0.18–1.93)	0.51 (0.16–1.68)
-	≥70	Overall			1.09 (0.33–3.61)	1.04 (0.14–7.77)	0.92 (0.12–7.05)	0.74 (0.10–5.62)
	≥/0			0.44 (0.11–1.78)	0.37 (0.09–1.52)	0.48 (0.11–2.07)	0.51 (0.12–2.20)	0.45 (0.10–1.95)
		IVICII	1.65 (0.64–4.29)	1.25 (0.48–3.26)	1.43 (0.55–3.75)	1.13 (0.13–9.75)	0.71 (0.08–6.56)	0.88 (0.10–7.52)
		Women	2.01 (0.69-5.88)	1.45 (0.49-4.26)	1.57 (0.54-4.54)	1.26 (0.13–11.94)	0.73 (0.07-7.29)	0.82 (0.09–7.61)
Portal vein thrombosis	<70	Overall	0.58 (0.15-2.30)	0.44 (0.11–1.72)	0.29 (0.07–1.17)	3.06 (1.29–7.24)	2.84 (1.19-6.74)	2.19 (0.89–5.37)
		Men	1.28 (0.33-4.95)	0.81 (0.21-3.09)	0.51 (0.13-2.04)	-	-	-
_		Women	-	-	-	5.30 (1.98–14.22)	4.28 (1.55–11.78)	3.95 (1.39–11.20)
	≥ 70	Overall	0.49 (0.10–2.28)	0.43 (0.10–1.87)	0.42 (0.09–1.91)	0.67 (0.23–1.97)	0.54 (0.19–1.56)	0.48 (0.17–1.38)
		Men	0.85 (0.17–4.38)	0.55 (0.11–2.66)	0.49 (0.10–2.46)	1.26 (0.36–4.41)	0.70 (0.23–2.17)	0.48 (0.17–1.38)
	- 0	Women	0.22 (0.01–3.38)	0.24 (0.01–3.80)	0.26 (0.02–4.47)	0.37 (0.09–1.52)	0.44 (0.10–2.01)	0.46 (0.11–2.04)
Pulmonary embolism	<70	Overall	1.52 (1.36–1.71)	0.99 (0.87–1.11)	0.78 (0.69–0.88)	1.20 (1.02–1.43)	0.89 (0.75–1.06)	0.71 (0.60–0.85)
		Men	1.93 (1.63–2.28)	1.05 (0.88–1.25)	0.85 (0.71–1.01)	1.56 (1.19–2.05)	0.97 (0.74–1.29)	0.77 (0.58–1.03)
-	> 70	Women	1.32 (1.13–1.56)	0.94 (0.79–1.10)	0.75 (0.64–0.89)	1.10 (0.88–1.37)	0.84 (0.67–1.05)	0.71 (0.57–0.89)
f	≥ 70	Overall	0.61 (0.55–0.68)	0.53 (0.48–0.59)	0.54 (0.49–0.60)	0.61 (0.54–0.69)	0.45 (0.40–0.51)	0.45 (0.39–0.50)
		Men	0.64 (0.55–0.75)	0.56 (0.48–0.65)	0.57 (0.49–0.66)	0.65 (0.54–0.77)	0.50 (0.42–0.59)	0.49 (0.41–0.59)
	<70	Women	0.59 (0.52–0.68)	0.51 (0.44–0.58)	0.52 (0.45–0.60)	0.58 (0.49–0.68)	0.42 (0.36–0.49)	0.42 (0.36–0.49)
Deep vein thrombosis	<70	Overall	1.38 (1.21–1.59)	1.03 (0.89–1.18)	0.82 (0.71–0.95)	1.05 (0.86–1.28)	0.85 (0.69–1.04)	0.73 (0.59–0.89)
		Men	1.93(1.60-2.33) 1.08(0.88-1.33)	$1.23 (1.01 - 1.49) \\ 0.87 (0.71 - 1.08)$	0.99 (0.81–1.20) 0.72 (0.58–0.89)	1.55(1.15-2.10) 0.88(0.67-1.15)	1.10(0.81-1.48) 0.74(0.56-0.97)	0.94 (0.69–1.28) 0.65 (0.50–0.86)
_	>70	Women		· /	0.61 (0.53–0.70)	0.88 (0.69–0.96)	(/	(/
:	≥ 70	Overall Men	0.69 (0.60–0.79) 0.66 (0.53–0.82)	$0.58 (0.51 - 0.67) \\ 0.59 (0.48 - 0.73)$	0.61(0.53-0.70) 0.61(0.49-0.76)	0.81(0.69-0.96) 0.95(0.74-1.23)	0.59 (0.50–0.70) 0.78 (0.60–1.01)	0.61 (0.52–0.73) 0.80 (0.61–1.05)
		Women	0.00 (0.53–0.82) 0.71 (0.59–0.85)	0.59(0.48-0.73) 0.59(0.49-0.70)	0.61(0.49-0.76) 0.62(0.52-0.74)	0.93 (0.74–1.23) 0.72 (0.58–0.90)	0.78(0.00-1.01) 0.49(0.40-0.61)	0.80 (0.81–1.03) 0.52 (0.41–0.64)
Other	<70	Overall	2.16 (1.47–3.19)	1.60 (1.07–2.37)	1.18(0.79-1.77)	1.64 (0.93–2.90)	1.34 (0.75–2.40)	0.32(0.41-0.04) 1.03(0.57-1.87)
Other	0</td <td>Men</td> <td>3.25 (1.93–5.50)</td> <td>2.03 (1.16 - 3.54)</td> <td>1.18(0.79-1.77) 1.46(0.83-2.57)</td> <td>2.14(0.86-5.34)</td> <td>1.54(0.75-2.40) 1.51(0.59-3.86)</td> <td>1.03(0.37-1.87) 1.03(0.39-2.70)</td>	Men	3.25 (1.93–5.50)	2.03 (1.16 - 3.54)	1.18(0.79-1.77) 1.46(0.83-2.57)	2.14(0.86-5.34)	1.54(0.75-2.40) 1.51(0.59-3.86)	1.03(0.37-1.87) 1.03(0.39-2.70)
		Women	1.48 (0.82–2.65)	1.20 (0.67–2.16)	0.98 (0.54–1.77)	1.55 (0.75–3.21)	1.31 (0.63–2.74)	1.03(0.39-2.70) 1.21(0.57-2.55)
_	≥70	Overall	1.13 (0.66–1.94)	0.97 (0.58–1.64)	1.01 (0.60 - 1.72)	0.86 (0.39–1.88)	0.66 (0.31–1.41)	0.67 (0.30–1.47)
	≥ 10	Men	1.13 (0.00–1.94) 1.50 (0.77–2.95)	1.25 (0.65 - 2.42)	1.01(0.00-1.72) 1.27(0.64-2.49)	1.51 (0.50–4.51)	1.09(0.36-3.34)	1.07 (0.33 - 3.44)
		Women	0.79 (0.31–2.04)	0.72 (0.30 - 1.75)	0.75(0.30-1.85)	0.42 (0.17 - 1.06)	0.36 (0.15–0.88)	0.36 (0.14–0.91)
All arterial events	<70	Overall	2.21 (2.12–2.31)	1.31(1.25-1.37)	0.94 (0.90–0.99)	1.45 (1.35–1.55)	1.08 (1.01–1.16)	0.88 (0.82–0.95)
	~/0	Men	3.06 (2.90–3.22)	1.31(1.25-1.57) 1.44(1.36-1.52)	0.94(0.90-0.99) 0.99(0.93-1.05)	2.17(1.99-2.38)	1.08(1.01-1.10) 1.19(1.08-1.31)	0.88(0.82-0.93) 0.91(0.82-1.00)
		Women	1.85 (1.71–1.99)	1.11(1.02-1.20)	0.99(0.93-1.03) 0.92(0.84-0.99)	1.44(1.30-1.60)	0.96(0.86-1.07)	0.91(0.82-1.00) 0.91(0.81-1.02)
_	≥70	Overall	0.90 (0.87–0.93)	0.69 (0.66–0.71)	0.72 (0.70–0.75)	1.15 (1.10–1.20)	0.69 (0.66–0.72)	0.71 (0.68–0.74)
-	2/0	Men	0.96 (0.91–1.00)	0.09 (0.00-0.71)	0.72 (0.70-0.73)	1.13(1.10-1.20) 1.17(1.11-1.25)	0.09 (0.00–0.72)	0.71(0.08-0.74) 0.74(0.70-0.79)
		Women	0.84 (0.80–0.89)	0.63 (0.60–0.66)	0.68 (0.65–0.71)	1.13 (1.06–1.20)	0.64 (0.61–0.68)	0.68 (0.64–0.73)

Outcome	Age	Sex		8 days post-vaccination		>	28 days post vaccination s	
	-		Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³	Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³
Myocardial infarction	<70	Overall	2.24 (2.12–2.37)	1.39 (1.30–1.47)	0.94 (0.88–1.00)	1.42 (1.29–1.55)	1.14 (1.04–1.26)	0.88 (0.80-0.97)
		Men	3.07 (2.87-3.28)	1.51 (1.40–1.62)	0.97 (0.90-1.05)	1.98 (1.76–2.23)	1.13 (1.00–1.28)	0.81 (0.71–0.93)
		Women	1.94 (1.74–2.17)	1.15 (1.03–1.30)	0.94 (0.83–1.06)	1.78 (1.54–2.05)	1.18 (1.02–1.37)	1.11 (0.95–1.30)
	≥ 70	Overall	0.93 (0.88–0.98)	0.74 (0.71–0.78)	0.74 (0.70–0.78)	1.19 (1.12–1.27)	0.78 (0.73–0.83)	0.75 (0.70-0.80)
		Men	0.99 (0.92–1.06)	0.81 (0.76–0.86)	0.79 (0.73–0.84)	1.20 (1.10–1.31)	0.82 (0.76–0.89)	0.76 (0.70–0.83)
1		Women	0.85 (0.78–0.92)	0.66 (0.61–0.72)	0.69 (0.63–0.74)	1.20 (1.08–1.33)	0.74 (0.67–0.81)	0.74 (0.67–0.82)
Ischaemic stroke ⁴	<70	Overall	2.18 (2.05–2.33)	1.23 (1.14–1.31)	0.90 (0.83–0.97)	1.46 (1.32–1.62)	1.00 (0.89–1.11)	0.80 (0.72–0.90)
		Men	3.05 (2.80–3.32)	1.38 (1.26–1.51)	0.95 (0.86–1.05)	2.40 (2.08–2.77)	1.26 (1.09–1.46)	0.91 (0.78–1.07)
		Women	1.76 (1.59–1.96)	1.05 (0.94–1.17)	0.85 (0.76–0.95)	1.18 (1.01–1.38)	0.77 (0.66–0.90)	0.73 (0.61–0.86)
	≥ 70	Overall	0.88 (0.84–0.93)	0.65 (0.63–0.68)	0.71 (0.68–0.75)	1.13 (1.06–1.19)	0.64 (0.60–0.67)	0.69 (0.66–0.73)
		Men	0.94 (0.88–1.00)	0.71 (0.66–0.75)	0.77 (0.72–0.82)	1.17 (1.07–1.27)	0.69 (0.64–0.75)	0.75 (0.69–0.81)
<u></u>		Women	0.84 (0.78–0.89)	0.61 (0.58–0.65)	0.68 (0.63–0.72)	1.09 (1.01–1.19)	0.60 (0.56–0.65)	0.66 (0.61–0.71)
Other arterial	<70	Overall	1.72 (1.28–2.31)	0.95 (0.70–1.30)	0.69 (0.50–0.94)	1.63 (1.10–2.43)	1.13 (0.74–1.72)	0.85 (0.55–1.32)
		Men	2.31 (1.58–3.37)	0.99 (0.66 - 1.49)	0.71 (0.47–1.07)	3.22 (2.02–5.13)	1.56 (0.95–2.58)	1.16 (0.69–1.96)
	. 70	Women	1.46 (0.90–2.37)	0.88 (0.54–1.45)	0.69 (0.42–1.15)	0.93 (0.43–1.99)	0.65 (0.30–1.43)	0.59 (0.26–1.33)
	≥ 70	Overall	0.59 (0.46–0.76)	0.51 (0.40–0.65)	0.52 (0.41–0.67)	0.64 (0.47–0.85)	0.47 (0.35–0.62)	0.46(0.34-0.62)
		Men	0.49 (0.35–0.69)	0.46 (0.32–0.65)	0.47 (0.33–0.66)	0.52 (0.37–0.74)	0.46 (0.32–0.66)	0.44 (0.31–0.64)
Haematological events		Women	0.74 (0.51–1.08)	0.59 (0.41–0.84)	0.60 (0.42–0.85)	0.83 (0.50–1.37)	0.50 (0.31-0.79)	0.49 (0.30-0.78)
Č Č	<70	Overall	2.10 (1.60–2.77)	1.48 (1.11–1.97)	1.00 (0.75–1.34)	2.03 (1.42-2.92)	1.54 (1.07-2.23)	0.97 (0.66–1.41)
Any thrombocytopenia	0</td <td>Men</td> <td>3.31 (2.23–4.91)</td> <td>2.07 (1.35–3.16)</td> <td>1.00(0.75-1.34) 1.19(0.78-1.83)</td> <td>2.03(1.42-2.92) 2.95(1.61-5.42)</td> <td>2.02(1.08-3.79)</td> <td>0.97(0.66-1.41) 0.93(0.49-1.78)</td>	Men	3.31 (2.23–4.91)	2.07 (1.35–3.16)	1.00(0.75-1.34) 1.19(0.78-1.83)	2.03(1.42-2.92) 2.95(1.61-5.42)	2.02(1.08-3.79)	0.97(0.66-1.41) 0.93(0.49-1.78)
		Women	1.50 (1.01–2.22)	1.17 (0.78–1.74)	0.97 (0.65–1.46)	1.58 (1.00-2.50)	1.32(0.83-2.08)	1.14(0.72-1.80)
	≥70	Overall	0.85 (0.64–1.13)	0.72 (0.54–0.95)	0.68 (0.51–0.90)	1.22 (0.87–1.71)	0.90 (0.64–1.25)	0.79 (0.56–1.12)
	≥/0	Men	0.85 (0.64–1.15)	0.72(0.54-0.93) 0.73(0.51-1.05)	0.68 (0.47–0.97)	1.22(0.87-1.71) 1.55(1.03-2.32)	1.12(0.75-1.67)	0.79(0.30-1.12) 0.95(0.62-1.46)
		Women	0.82 (0.53–1.29)	0.71 (0.46–1.09)	0.68 (0.44–1.07)	0.84 (0.48 - 1.48)	0.63 (0.36 - 1.09)	0.57 (0.32 - 1.02)
Other events		women	0.02 (0.55 1.27)	0.71 (0.10 1.09)	0.00 (0.11 1.07)	0.01 (0.10 1.10)	0.05 (0.50 1.07)	0.57 (0.52 1.02)
Haemorrhagic stroke ⁵	<70	Overall	1.39 (1.13–1.71)	0.83 (0.67–1.03)	0.77 (0.62–0.96)	1.31 (1.00–1.73)	0.90 (0.68–1.19)	0.86 (0.65–1.15)
The monormagic subke	.,0	Men	1.65 (1.22–2.23)	0.86 (0.63–1.18)	0.77 (0.57–1.05)	1.43 (0.89–2.29)	0.86 (0.53–1.40)	0.77 (0.47–1.25)
		Women	1.28 (0.95–1.72)	0.80 (0.59–1.08)	0.78 (0.58–1.05)	1.34 (0.95–1.88)	0.89 (0.62–1.26)	0.92 (0.65–1.31)
	≥70	Overall	0.80 (0.69–0.91)	0.59 (0.52–0.68)	0.65 (0.57–0.74)	1.28 (1.09–1.50)	0.72 (0.62–0.84)	0.80 (0.68–0.94)
		Men	0.82 (0.67–1.01)	0.59 (0.48–0.71)	0.64 (0.52–0.78)	1.45 (1.14–1.83)	0.78 (0.62–0.98)	0.86 (0.68–1.09)
		Women	0.78 (0.65-0.94)	0.60 (0.50-0.72)	0.66 (0.55-0.79)	1.16 (0.93–1.44)	0.68 (0.56-0.84)	0.76 (0.61-0.93)
Mesenteric thrombosis	<70	Overall	1.61 (1.10-2.36)	0.84 (0.56–1.26)	0.65 (0.43-0.97)	1.77 (1.11–2.84)	1.08 (0.66–1.75)	0.83 (0.50-1.37)
		Men	2.91 (1.78-4.75)	1.29 (0.77-2.17)	0.97 (0.57–1.64)	2.21 (0.99-4.94)	1.15 (0.50-2.62)	0.82 (0.35-1.91)
		Women	0.91 (0.49–1.67)	0.55 (0.29–1.03)	0.45 (0.23–0.86)	1.61 (0.90-2.88)	1.09 (0.60–1.98)	0.94 (0.50-1.75)
	≥ 70	Overall	0.72 (0.57-0.90)	0.54 (0.43-0.67)	0.54 (0.44-0.68)	1.06 (0.81–1.37)	0.61 (0.48–0.78)	0.59 (0.45-0.76)
		Men	0.57 (0.37–0.86)	0.41 (0.27–0.61)	0.42 (0.28–0.62)	0.82 (0.53–1.29)	0.44 (0.29–0.66)	0.42 (0.27-0.65)
		Women	0.80 (0.61–1.04)	0.61 (0.47–0.80)	0.62 (0.48–0.81)	1.18 (0.86–1.63)	0.72 (0.53–0.98)	0.70 (0.51-0.96)
Lower limb fracture	<70	Overall	1.44 (1.31–1.59)	1.03 (0.93–1.14)	0.93 (0.84–1.02)	1.24 (1.08–1.42)	0.95 (0.83–1.09)	0.89 (0.78–1.03)
		Men	1.19 (0.99–1.42)	0.94 (0.78–1.12)	0.85 (0.71–1.02)	0.99 (0.74–1.31)	0.83 (0.62–1.11)	0.80 (0.60-1.07)
		Women	1.49 (1.33–1.67)	1.08 (0.96–1.21)	0.98 (0.87–1.10)	1.27 (1.09–1.48)	1.00 (0.85–1.17)	0.94 (0.80-1.11)
	≥70	Overall	0.99 (0.93–1.05)	0.65 (0.62–0.69)	0.69 (0.66–0.73)	1.48 (1.38–1.59)	0.67 (0.63-0.72)	0.71 (0.66–0.76)
		Men	0.95 (0.85-1.06)	0.58 (0.52-0.64)	0.63 (0.57-0.70)	1.60 (1.40–1.83)	0.65 (0.57-0.73)	0.69 (0.61-0.79)
		Women	1.00 (0.93-1.07)	0.68 (0.64-0.73)	0.72 (0.67–0.77)	1.42 (1.30–1.55)	0.68 (0.63-0.73)	0.71 (0.65-0.77)

Outcome	Age	Sex	1-28	8 days post-vaccination		>	28 days post vaccination s	
			Unadjusted ¹	Age and sex	Fully adjusted ³	Unadjusted ¹	Age and sex adjusted ²	Fully adjusted ³
				adjusted ²				
Death	<70	Overall	0.74 (0.69-0.79)	0.35 (0.32-0.37)	0.24 (0.22-0.26)	0.91 (0.84-1.00)	0.52 (0.48-0.57)	0.33 (0.30-0.37)
		Men	1.06 (0.97-1.17)	0.39 (0.36-0.43)	0.28 (0.25-0.31)	1.62 (1.44-1.82)	0.69 (0.61-0.79)	0.44 (0.39-0.51)
		Women	0.56 (0.50-0.63)	0.29 (0.26-0.33)	0.22 (0.19-0.25)	0.66 (0.58-0.75)	0.38 (0.34-0.44)	0.28 (0.25-0.33)
	≥70	Overall	0.22 (0.22-0.23)	0.16 (0.16-0.16)	0.19 (0.19-0.20)	0.30 (0.29-0.31)	0.16 (0.16-0.16)	0.19 (0.18-0.19)
		Men	0.23 (0.22-0.24)	0.16 (0.15-0.16)	0.19 (0.18-0.20)	0.33 (0.32-0.34)	0.16 (0.15-0.17)	0.19 (0.18-0.19)
		Women	0.21 (0.20-0.22)	0.16 (0.16-0.17)	0.20 (0.19-0.20)	0.27 (0.26-0.28)	0.16 (0.15-0.17)	0.19 (0.18-0.19)

¹Stratifed by region ²Adjusted for age, age², sex and stratified by region ³Adjusted for age, age², sex, ethnicity, deprivation, smoking and co-morbidities, and stratified by region ⁴Ischaemic stroke: including ischaemic stroke, stroke of uncertain cause, and spinal stroke ⁵Hemorrhagic stroke: including intracranial hemorrhage and subarachnoid hemorrhage

Supplementary table 2 (a) Fully adjusted hazard ratios (HRs) for the association of ChAdOx1-S and BNT162b2 with venous events 1-28 and >28 days after vaccination, within prespecified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy

		ChAdOx1-S vaccine						BNT	162b2 vacc	ine	
		N (Events)	Post vaccination		Post vaccination	>28 days	N (Events)	Post vaccination	≤28 days	Post vaccination	>28 days
Subgroup		3001	HR (95% CI) ¹	P value	HR (95% CI) ¹	P value	3133	HR (95% CI) ¹	P value	HR (95% CI) ¹	P value
	18-29	40	2.30 (1.63-3.25)		1.29 (0.58-2.90)		29	0.99 (0.60-1.62)		0.99 (0.57-1.71)	
	30-39	63	1.33 (1.01-1.75)		0.85 (0.46-1.59)		60	0.90 (0.65-1.25)		0.71 (0.47-1.07)	
	40-49	145	1.32 (1.09-1.61)		1.52 (1.09-2.13)		122	0.96 (0.77-1.21)		0.75 (0.56-1.01)	
A	50-59	270	0.93 (0.81-1.07)	< 0.0001	1.00 (0.77-1.30)	0.003	237	0.78 (0.66-0.92)	0.005	0.69 (0.55-0.86)	0.839
Age groups	60-69	618	0.87 (0.79-0.96)	<0.0001	0.89 (0.73-1.07)	0.003	359	0.78 (0.69-0.89)	0.003	0.67 (0.55-0.83)	0.839
	70-79	1124	0.75 (0.69-0.82)		0.79 (0.71-0.88)		823	0.69 (0.62-0.77)		0.73 (0.65-0.82)	
	80-89	546	0.79 (0.69-0.89)		0.73 (0.63-0.84)		1255	0.63 (0.56-0.70)		0.67 (0.61-0.74)	
	>90	195	0.76 (0.62-0.94)		0.75 (0.59-0.95)		248	0.80 (0.65-0.99)		0.67 (0.55-0.81)	
Sex	Male	1338	0.81 (0.75-0.87)	0.029	0.74 (0.66-0.82)	0.005	1423	0.70 (0.64-0.76)	0.150	0.66 (0.60-0.72)	0.024
Sex	Female	1663	0.90 (0.84-0.97)	0.029	0.89 (0.81-0.98)	0.005	1710	0.75 (0.70-0.81)	0.150	0.74 (0.69-0.81)	0.024
	White	2856	0.86 (0.82-0.91)		0.82 (0.76-0.89)		2977	0.72 (0.68-0.77)		0.71 (0.66-0.76)	
	Asian or Asian British	38	0.51 (0.34-0.77)		0.66 (0.38-1.14)		56	0.69 (0.48-0.98)		0.57 (0.38-0.86)	
	Black or Black British	53	0.91 (0.66-1.25)		0.62 (0.35-1.10)		42	0.62 (0.41-0.94)		0.61 (0.39-0.97)	
Ethnicity	Mixed	10	0.47 (0.21-1.06)	0.018	0.76 (0.28-2.06)	0.429	12	0.74 (0.36-1.51)	0.002	0.43 (0.16-1.17)	0.691
·	Other Ethnic Groups	17	0.73 (0.37-1.43)		1.63 (0.80-3.32)		23	1.30 (0.75-2.24)		0.94 (0.48-1.84)	
	Unknown	21	1.11 (0.65–1.89)		1.14 (0.50-2.58)		15	0.74 (0.36-1.51)		0.68 (0.32-1.47)	
	Missing	6	2.59 (1.05-6.42)		1.29 (0.18-9.32)		8	3.85 (1.67-8.87)		1.33 (0.33-5.43)	
	1-2 (least)	564	0.76 (0.68-0.85)		0.76 (0.65-0.89)		489	0.65 (0.57-0.74)		0.54 (0.47-0.62)	
	3-4	560	0.86 (0.77-0.96)		0.80 (0.68-0.93)		576	0.76 (0.67-0.85)		0.70 (0.62-0.80)	
Deprivation	5-6	625	0.90 (0.81-1.00)	0.138	0.82 (0.71-0.96)	0.43	606	0.70 (0.62-0.79)	0.095	0.67 (0.59-0.76)	< 0.000
	7-8	632	0.87 (0.78-0.97)		0.80 (0.69-0.93)		687	0.73 (0.65-0.82)		0.71 (0.63-0.80)	
	9-10 (most)	609	0.91 (0.81–1.01)		0.92 (0.79–1.06)		770	0.81 (0.72-0.91)		0.88 (0.79–0.98)	
	No	3001	0.86 (0.82-0.91)		0.82 (0.76-0.89)	0.127	3132	0.73 (0.69-0.78)	0.014	0.71 (0.66-0.75)	0.050
Prior thrombocytopenia	Yes	0	0.54 (0.35-0.82)	0.030	0.54 (0.31-0.93)	0.127	<5	0.37 (0.21-0.63)	0.014	0.58 (0.38-0.89)	0.372
	No	2986	0.86 (0.81-0.91)		0.82 (0.76-0.89)		3116	0.73 (0.69–0.77)		0.70 (0.66-0.75)	
Prior thrombophilia	Yes	15	0.50 (0.27-0.94)	0.093	0.38 (0.14-1.03)	0.130	17	0.48 (0.23-0.99)	0.254	0.68 (0.34-1.37)	0.924
	No	3001	0.95 (0.90-1.01)		0.96 (0.88–1.05)		3133	0.80 (0.76-0.86)		0.78 (0.73-0.84)	
Prior venous event	Yes	0	0.54 (0.48–0.61)	< 0.0001	0.42 (0.35–0.50)	< 0.0001	0	0.44 (0.38–0.51)	< 0.0001	0.44 (0.38–0.51)	< 0.000
	No	2839	0.88 (0.83-0.93)		0.85 (0.79-0.93)		3012	0.74 (0.70-0.79)		0.72 (0.68-0.77)	
Prior COVID infection	Yes	162	0.60 (0.49-0.74)	< 0.001	0.49 (0.37-0.64)	< 0.0001	121	0.47 (0.36-0.61)	0.001	0.45 (0.34-0.58)	< 0.00
	No	2996	1.15 (0.99–1.35)		1.03 (0.77–1.39)		3129	0.84 (0.70–1.00)		0.77 (0.61–0.97)	
ОСР	Yes	5	0.69 (0.22-2.17)	0.382	1.26 (0.31-5.09)	0.786	<5	0.33 (0.08–1.34)	0.195	0.34 (0.08–1.41)	0.270
	No	2972	0.78 (0.73–0.83)		0.75 (0.69–0.82)		3112	0.69 (0.65-0.73)		0.66 (0.62-0.71)	
HRT	Yes	29	0.92 (0.56–1.50)	0.514	0.96 (0.45–2.05)	0.532	21	0.57 (0.30–1.08)	0.554	0.65 (0.34–1.23)	0.949
	No	2759	0.98 (0.92–1.03)		0.98 (0.90–1.07)		2875	0.84 (0.79–0.89)		0.83 (0.77–0.89)	
Anticoagulant	Yes	242	0.34 (0.29–0.40)	< 0.0001	0.28 (0.22–0.35)	< 0.0001	258	0.25 (0.21–0.31)	< 0.0001	0.27 (0.22–0.32)	< 0.000
	No	2503	0.89 (0.84–0.95)		0.84 (0.77–0.92)		2513	0.75 (0.71–0.80)		0.72 (0.67–0.77)	
Antiplatelet	Yes	498	0.69 (0.61–0.78)	< 0.001	0.73 (0.62–0.85)	0.081	620	0.62 (0.55–0.71)	0.011	0.66 (0.58–0.75)	0.220
	No	2603	0.88 (0.83–0.93)		0.87 (0.80-0.95)		2680	0.74 (0.70–0.79)		0.72 (0.67–0.77)	
Prior MI or stroke	Yes	398	0.71 (0.62–0.82)	0.004	0.58 (0.48–0.69)	< 0.0001	453	0.62 (0.53–0.72)	0.021	0.63 (0.55–0.73)	0.086
	No	2363	0.88 (0.83–0.93)		0.85 (0.78–0.93)		2456	0.74 (0.70–0.79)		0.71 (0.66–0.76)	
Prior diabetes	Yes	638	0.78 (0.70–0.87)	0.053	0.72 (0.62–0.83)	0.034	677	0.67 (0.60–0.76)	0.149	0.69 (0.61–0.78)	0.639


Supplementary table 2 (D) Fully adjusted nazard ratios (HKS) for the association of UnAdOx1-S and BN1102D2 with arterial events 1-28 and >28 days after vaccination, within prespecified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy

			ChAo	dOx1-S vac	cine			BNI	162b2 vacc	ine	
		N (Events)	Post vaccination	≦28 days	Post vaccination	>28 days	N (Events)	Post vaccination	≤28 days	Post vaccination	>28 days
Subgroup	All arterial	12890	HR (95% CI) ¹	P value	HR (95% CI) ¹	P value	16759	HR (95% CI) ¹	P value	HR (95% CI) ¹	P value
	18-29	12	1.72 (0.89–3.33)		1.84 (0.59–5.73)		21	2.01 (1.13-3.57)		1.85 (0.96-3.59)	
	30-39	54	1.51 (1.11-2.06)		1.54 (0.87-2.72)		67	1.36 (1.00-1.86)		1.09 (0.74–1.61)	
	40-49	277	1.37 (1.20–1.57)		1.29 (0.99–1.69)		284	1.17 (1.01–1.36)		0.86 (0.70-1.05)	
Age groups	50-59	963	0.98 (0.91-1.05)	< 0.0001	0.89 (0.76–1.04)	0.031	1062	1.06 (0.98–1.14)	< 0.0001	0.81 (0.72-0.91)	< 0.0001
rige groups	60-69	2442	0.85 (0.81-0.90)	-0.0001	0.90 (0.82-0.99)	0.051	1705	0.89 (0.84-0.95)	-0.0001	0.83 (0.76-0.92)	-0.0001
	70-79	5030	0.90 (0.86-0.94)		0.93 (0.88–0.99)		3993	0.85 (0.81-0.89)		0.91 (0.86-0.96)	
	80-89	2826	0.86 (0.81–0.91)		0.88 (0.82-0.94)		7733	0.74 (0.71–0.78)		0.79 (0.76–0.82)	
	>90	1286	0.85 (0.78-0.93)		0.86 (0.78-0.94)		1894	0.72 (0.66-0.79)		0.78 (0.73-0.84)	
Sex	Male	7116	0.78 (0.75-0.80)	< 0.0001	0.75 (0.71–0.79)	< 0.0001	9292	0.77 (0.74–0.79)	< 0.0001	0.71 (0.68–0.73)	< 0.0001
	Female	5774	0.89 (0.86-0.93)	010001	0.87 (0.83-0.92)	0.0001	7467	0.85 (0.82-0.88)	010001	0.89 (0.85-0.92)	010001
	White	11729	0.82 (0.79–0.84)		0.80 (0.77–0.84)		15492	0.80 (0.78–0.82)		0.79 (0.76–0.81)	
	Asian or Asian British	647	0.84 (0.76-0.93)		0.74 (0.64–0.86)		728	0.75 (0.67–0.84)		0.63 (0.56–0.71)	
	Black or Black British	217	0.90 (0.75–1.07)		0.89 (0.70–1.15)		190	0.77 (0.62–0.94)		0.79 (0.64–0.99)	
Ethnicity	Mixed	72	1.19 (0.90–1.57)	< 0.0001	0.56 (0.32-0.98)	0.180	85	1.10 (0.82–1.49)	< 0.0001	0.81 (0.57–1.17)	< 0.0001
	Other Ethnic Groups	113	0.93 (0.73–1.18)		0.90 (0.64–1.28)		121	0.89 (0.69–1.15)		0.76 (0.57–1.01)	
	Unknown	80	0.88 (0.67–1.16)		0.75 (0.49–1.16)		103	0.87 (0.64–1.18)		1.09 (0.83–1.44)	
	Missing	32	3.01 (1.98-4.57)		1.91 (0.89-4.08)		40	2.87 (1.81-4.56)		2.87 (1.80-4.58)	
	1-2 (least)	2498	0.76 (0.71–0.80)		0.71 (0.66–0.77)	< 0.0001	2788	0.75 (0.71–0.79)		0.69 (0.65–0.73)	
	3-4	2514	0.81 (0.76-0.85)		0.76 (0.71–0.82)		2980	0.76 (0.72–0.81)		0.74 (0.69–0.78)	
Deprivation	5-6	2683	0.85 (0.81-0.90)	< 0.001	0.79 (0.74–0.85)		3489	0.78 (0.74–0.83)	< 0.0001	0.79 (0.75–0.84)	< 0.0001
	7-8	2616	0.83 (0.78–0.87)		0.86 (0.80-0.92)		3693	0.82 (0.78–0.87)		0.83 (0.79–0.88)	
	9-10 (most)	2541	0.89 (0.85-0.95)		0.88 (0.82-0.95)		3772	0.90 (0.85-0.95)		0.85 (0.80-0.89)	
Prior thrombocytopenia	No	12889	0.82 (0.80-0.85)	0.334	0.80 (0.77–0.84)	0.499	16758	0.80 (0.78–0.82)	0.920	0.78 (0.76–0.81)	0.136
· · · · · · · · · · · · · · · · · · ·	Yes	<5	0.75 (0.61–0.91)		0.73 (0.57–0.95)		<5	0.81 (0.66–1.00)		0.67 (0.54–0.82)	
Prior thrombophilia	No	12864	0.82 (0.80-0.85)	0.059	0.80 (0.77–0.83)	0.620	16735	0.80 (0.78–0.82)	0.499	0.78 (0.76–0.81)	0.098
*	Yes	26	0.48 (0.28–0.84)		0.66 (0.32–1.39)		24	0.66 (0.38–1.15)		0.43 (0.21–0.88)	
Prior venous event	No	12874	0.83 (0.81–0.85)	0.029	0.80 (0.77–0.84)	0.504	16751	0.81 (0.78–0.83)	0.022	0.79 (0.76–0.81)	0.002
	Yes No	16	0.73 (0.66–0.82)		0.77 (0.67–0.88)		<u>8</u> 16234	0.70 (0.63-0.79)		0.66 (0.59–0.74)	
Prior COVID infection	Yes	12227 663	0.84 (0.81–0.86) 0.63 (0.57–0.70)	< 0.0001	0.83 (0.79–0.86) 0.51 (0.45–0.59)	< 0.0001	525	0.81 (0.79–0.84) 0.57 (0.50–0.65)	< 0.0001	0.80 (0.77–0.82) 0.51 (0.45–0.59)	< 0.0001
	No	12889	0.03 (0.37–0.70)		0.89 (0.67–1.18)		16759	0.91 (0.79–1.06)		0.94 (0.75–1.16)	
ОСР	Yes	<5	0.91(0.79-1.03) 0.89(0.12-6.51)	0.983	0.89 (0.67–1.18) 0.00 (0.00–0.00)	< 0.0001	0	0.00 (0.00–0.00)	< 0.0001	0.94 (0.75–1.16) 0.00 (0.00–0.00)	< 0.0001
	No	12832	0.85 (0.82–0.87)		0.84 (0.80–0.88)		16671	0.81 (0.78–0.83)		0.79 (0.76–0.81)	
HRT	Yes	58	1.01 (0.73 - 1.40)	0.293	0.79 (0.45–1.37)	0.820	88	1.10 (0.79–1.51)	0.061	1.08 (0.77 - 1.52)	0.070
	No	10726	0.84(0.82-0.87)		0.82 (0.78–0.85)		13715	0.83 (0.81–0.86)		0.80 (0.77–0.83)	
Anticoagulant	Yes	2164	0.74 (0.69–0.79)	< 0.001	0.74 (0.68–0.80)	0.015	3044	0.66 (0.62–0.70)	< 0.0001	0.71 (0.67–0.76)	< 0.001
	No	7636	0.99 (0.96–1.03)		1.06 (1.01–1.11)		9770	0.96 (0.93–0.99)		1.05 (1.01–1.09)	
Antiplatelet	Yes	5254	0.65 (0.63–0.68)	< 0.0001	0.59(0.55-0.62)	< 0.0001	6989	0.65 (0.63–0.67)	< 0.0001	0.55 (0.53–0.57)	< 0.0001
	No	6931	1.09 (1.05–1.13)		1.18 (1.12–1.24)		9428	1.08 (1.04–1.12)		1.22 (1.17–1.26)	
Prior MI or stroke	Yes	5959	0.64 (0.61–0.66)	< 0.0001	0.60 (0.57–0.63)	< 0.0001	7331	0.60 (0.57–0.62)	< 0.0001	0.51 (0.49–0.53)	< 0.0001
	No	8742	0.85 (0.83–0.88)		0.84 (0.80–0.88)		11689	0.84 (0.82–0.87)		0.82 (0.79–0.85)	
Prior diabetes	Yes	4148	0.77 (0.73–0.80)	< 0.0001	0.73 (0.69–0.78)	< 0.001	5070	0.72 (0.69–0.76)	< 0.0001	0.70 (0.67–0.74)	< 0.0001
	res	4148	0.77(0.73-0.80)		0.73 (0.09-0.78)		3070	0.72 (0.09-0.76)		0.70 (0.67-0.74)	


medRxiv preprint doi: https://doi.org/10.1101/2021.08.18.21262222; this version posted January 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Supplementary table 3. Characteristics of patient who had an ICVT event before and after vaccination. Only percentage are presented, as disclosure control does not allow numbers <5 to be released

VT before cination % <210 40 60 19 42 30 6 3 15 5 2 1 75	ICVT after ChAdOx1, % <40 33 67 17 22 36 11 14 6 3 0 0 0	ICVT after BNT162b, % <20 21 79 0 26 16 21 37 0 0 0 0 0	p-value ¹ <0.0001 0.24 <0.0001
<210 40 60 19 42 30 6 3 15 5 2 1	$ \begin{array}{r} <40 \\ 33 \\ 67 \\ 17 \\ 22 \\ 36 \\ 11 \\ 14 \\ 6 \\ 3 \\ 0 \\ \end{array} $	<20 21 79 0 26 16 21 37 0 0 0	0.24 <0.0001
60 19 42 30 6 3 15 5 2 1	67 17 22 36 11 14 6 3 0	79 0 26 16 21 37 0 0	<0.0001
19 42 30 6 3 15 5 2 1	$ \begin{array}{r} 17 \\ 22 \\ 36 \\ 11 \\ 14 \\ 6 \\ 3 \\ 0 \\ \end{array} $	0 26 16 21 37 0 0	<0.0001
42 30 6 3 15 5 2 1	22 36 11 14 6 3 0	26 16 21 37 0 0	
30 6 3 15 5 2 1	36 11 14 6 3 0	16 21 37 0 0	
6 3 15 5 2 1	36 11 14 6 3 0	16 21 37 0 0	
3 15 5 2 1	14 6 3 0	37 0 0	
3 15 5 2 1	14 6 3 0	37 0 0	
15 5 2 1	3 0	0 0	
2 1	0	-	
2 1		0	
	0		0.29
75		0	0.38
	92	100	
1	0	0	
29	17	11	
20	14	26	0.19
		21	
13	25	16	
13	19	26	
19	28	11	
21		32	0.5
		11	<0.0001 0.01
		0	
	6	5	< 0.0001
1	0	0	0.05 <0.0001 <0.0001
6	6	0	
10	17	37	
26	36	16	< 0.0001
37		42	< 0.0001
17		37	< 0.0001
2	11	16	0.78
<1	3	0	0.61
5	11	32	0.25 <0.0001
18	8	11	
2	3	0	0.03
5	6	16	0.01
15	28	42	<0.0001 <0.0001 <0.0001
12	22	26	
10	11	11	
4	0	0	< 0.0001
1	0	0	0.05
71	50	58	0.04
29		42	0.04
31	11		
			0.02
	$\begin{array}{c} 29\\ 20\\ 25\\ 13\\ 13\\ 19\\ 21\\ 57\\ 5\\ 3\\ 8\\ 1\\ 6\\ 10\\ 26\\ 37\\ 17\\ 2\\ <1\\ 5\\ 18\\ 2\\ \\ 5\\ 15\\ 12\\ 10\\ 4\\ 1\\ 71\\ 29\\ \end{array}$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

¹ Approximation if Chi squared test included one or more zero counts; ² Index of Multiple Deprivation deciles where 1 indicates least deprived and 10 indicates most deprived; ³ After 31/12/2019 and prior to 08/12/2020; ⁴ In the last year; ⁵ The category '6+' contained no individuals and so was excluded.



Supplementary figure 1: Cumulative incidence of vaccines of different types during follow up



Supplementary figure 2: Adjusted hazard ratios for portal vein thrombosis, other venous events, and death after ChAdOx1-S or BNT162b2 vaccine